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ABSTRACT 
 
 
Two of the hallmarks of neurodegenerative disorders, 
such as Alzheimer‟s disease (AD), are (1) the appearance of 
proteinaceous deposits in inclusion bodies containing 
aggregates of ubiquitinated proteins and (2) activated 
microglia and astrocytes surrounding the diseased neurons. 
In Alzheimer‟s disease, the intracellular inclusion bodies 
are known as neurofibrilary tangles (NFT). The mechanisms 
leading to inclusion body formation and their role in the 
progression of neurodegeneration are still largely unknown. 
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Many of the proteins that accumulate in inclusion 
bodies depend on the ubiquitin/proteasome pathway (UPP) for 
their degradation. This pathway is responsible for the bulk 
(~80%) of intracellular protein degradation. Because of its 
central role in the removal of mutated and misfolded 
proteins by degradation, disruption of the UPP is 
particularly relevant to the accumulation of aberrant 
proteins observed in aging-related neurodegenerative 
disorders, such as AD. Besides containing ubiquitinated 
proteins, one of the major components of NFTs is the 
microtubule associated protein “tau”. Tau protein is 
abundant in neurons and is a highly soluble protein. Tau 
must be cleaved first to function as a seed for its self 
aggregation.  
Our main hypothesis is that toxic inflammation factors 
released by microglia and astrocytes will damage proteins 
in neurons causing protein misfolding. An abrupt or chronic 
increase in damaged proteins will overwhelm the proteasome, 
particularly in old age when proteasome activity is clearly 
impaired. If not resolved, the ensuing accumulation of 
ubiquitinated proteins is potently toxic and drives the 
cell to activate a death pathway, therefore launching 
apoptosis. Caspase activation associated with apoptosis 
leads to caspase-mediated proteolysis of a variety of 
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proteins including tau, which is a microtubule stabilizing 
protein. Tau cleavage will destabilize microtubules and 
cause the collapse of the cell structure. In addition, tau 
cleavage will promote protein aggregation. All of these 
events culminate in neurodegeneration.  
We tested our hypothesis by incubating neuronal cells 
with the cytotoxic product of inflammation prostaglandin J2 
(PGJ2). As we proposed, the initial event observed upon 
PGJ2 treatment was the accumulation of ubiquitinated 
proteins. This was followed by apoptosis coinciding with 
caspase activation and tau cleavage, culminating in protein 
aggregation and cell death. In other studies, we 
established a direct correlation between proteasome 
impairment (accomplished by a genetic manipulation of its 
chymotrypsin-like activity) with an increased vulnerability 
to stress conditions induced by the heavy metal cadmium. 
Finally, we identified a unique aging-dependent mechanism 
that contributes to proteasome dysfunction in Drosophila 
melanogaster. Our studies were the first to show that the 
major proteasome form in old flies is the weakly active 20S 
core particle, while in younger flies the fully assembled 
26S holoenzyme is the preponderant proteasome form.  
In conclusion, these studies support the view that 
maintaining proteasome activity is critical to cell 
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survival. If proteasome activity is disrupted by 
inflammation or oxidative stress or even by the build-up of 
mutant proteins, this will have a catastrophic effect on 
cell survival resulting in the induction of apoptosis. The 
ensuing activation of caspase-mediated proteolysis will 
lead to partial cleavage of a variety of proteins including 
tau that will in turn promote protein aggregation 
culminating in neurodegeneration. This neurodegenerative 
process is exacerbated at later stages in life, because 
proteasome function seems to decline abruptly at an old 
age. A better understanding of the mechanisms leading to 
the build-up of protein aggregates will open up new targets 
for treatment of neurodegenerative disorders, such as AD, 
that are associated with chronic inflammation and protein 
aggregation. 
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CHAPTER I 
 
 
 
INTRODUCTION 
 
 
Portions of this introduction were published in the journal 
Neurodegenererative Disorders 2006; 3(6):313-9 
 
 
“It may take inflammation, phosphorylation and 
ubiquitination to 'tangle' in Alzheimer's disease” 
 
By 
 
Arnaud, L.(1), Robakis, N.K.(2) & Figueiredo-Pereira, M.E.(1) 
 
(1)Department of Biological Sciences, Hunter College of 
City University of New York 
 
and 
  
 (2)Department of Psychiatry and Fishberg Research Center 
for Neurobiology, Mount Sinai School of Medicine, New York 
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Neurofibrillary tangles are one of the pathologic 
hallmarks of Alzheimer‟s disease (AD). Their major 
component is tau, a protein that becomes 
hyperphosphorylated and accumulates into insoluble paired 
helical filaments. During the course of the disease such 
filaments aggregate into bulky  that get ubiquitinated. 
What triggers the formation is not known, but 
neuroinflammation could play a role. Neuroinflammation is 
an active process detectable in the earliest stages of AD. 
The neuronal toxicity associated with inflammation makes 
it a potential risk factor in the pathogenesis of chronic 
neurodegenerative diseases, such as AD. Determining the 
sequence of events that lead to this devastating disease 
has become one of the most important goals for AD 
prevention and treatment. In this introduction we focus on 
three topics relevant to AD pathology and to  formation: 
(1) what triggers CNS inflammation resulting in glia 
activation and neuronal toxicity; (2) how products of 
inflammation might change the substrate specificity of 
kinases/phosphatases leading to tau phosphorylation at 
pathological sites; (3) the relationship between the 
ubiquitin/proteasome pathway and tau ubiquitination and 
accumulation in .  
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The overall aim of this introduction is to provide a 
summary of important contributions supporting the view 
that CNS inflammation might be a critical contributor to 
AD pathology. Neuronal cell death resulting from 
neuroinflammatory processes may have devastating effects 
as, in the vast majority of cases neurons lost to disease 
cannot be replaced. In order to design therapies that will 
prevent endangered neurons from dying, it is critical that 
we learn more about the effects of neuroinflammation and 
its products. 
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1.1. ALZHEIMER’S DISEASE AND INFLAMMATION 
Alzheimer‟s disease is a chronic, age-related 
neurodegenerative disorder. This dementia affects mostly 
people 65 years or older. Its pathological characteristics 
are the presence of senile plaques and neurofibrillary 
tangles in the brain. The senile plaques are composed of 
aberrant aggregates of amyloid β peptide while the  
consist of hyperphosphorylated tau. Over the last decade 
it has become clear that chronic neuroinflammation is 
another constant feature of AD 
1
. Indeed neuroinflammation, 
long considered to be peripheral to the disease, is being 
increasingly accepted as being associated with the onset 
of this neurodegenerative disorder 
2-4
. 
As its peripheral counterpart, neuroinflammation is 
widely regarded as a double-edged sword: it can exert both 
neuroprotective and neurotoxic functions. The mechanisms 
that switch between neuroprotection and neurotoxicity are 
poorly understood. In the case of  neuroinflammation is 
labeled chronic because of its extended time course. 
Exposing the brain to such a prolonged process over months 
even years will inevitably lead to tissue damage. Glia and 
neuronal interactions during inflammation are thus 
particularly relevant to neurodegeneration (reviewed in 
5
). 
At the histological level, the main actors of CNS 
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inflammation are the activated microglia 
6
, the astrocytes 
and, to a lesser exten, the neurons themselves 
7
. In 
addition, numerous studies have provided evidence for an 
increased activation of the complement system in areas of 
AD pathology 
8;9
. Studies are still trying to assess the 
degree of inflammation in the brain of AD patients and the 
CSF markers fail to reflect exactly the situation of the 
isolated brain, highlighting the difficulty of assessing 
the real degree of inflammation in the brain 
10-13
. 
The question persists regarding the role of 
inflammation in AD: Is it a driving force, a bystander or 
a beneficial response 
14
? If inflammation cannot be ruled 
as the initiator of the disease, its systematic presence 
in the pathological areas of the brain and the decrease of 
pathology after treatment with anti-inflammatory drugs 
links it to the development of the disease. If the acute 
activation of the microglia might be beneficial for the 
brain after injury, its chronic activation might not. 
Chronic inflammation may induce the release of toxic 
inflammatory products suspected to worsened the pathology 
and prevent the proper removal of waste products, 
emphasizing the necessity of a close control of 
inflammation. Microglia activation into phagocytic glial 
cells might be beneficial for the removal of toxic 
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aggregates or dying cells. Neurotoxic glial cells release 
inflammatory factors fueling the toxic course of events 
leading to cell death. Aβ aggregates seem to activate an 
inflammation response at the level of gene expression in 
microglia. Aβ triggers neurotoxic glial activation and 
release of inflammatory factors, preventing microglia from 
phagocyting the Aβ aggregates, thus contributing to 
neuronal toxicity. This would support the hypothesis that 
Aβ accumulation activates chronically microglia. Since 
there is no Aβ phagocytosis, Aβ remains leading to chronic 
microglia activation and inducing the release of 
inflammation factors toxic for the neurons 
15
. 
In P301S Tg mice the activation of microglia precedes 
tau pathology generated by the transgene and the 
abrogation of tau-induced microglial activation could 
retard progression of these disorders 
16
. 
Microglia are immunocompetent cells that take up 
residence in the developing brain as fetal macrophages. 
They are the first responsive element to brain damage or 
insult. Studies have shown that amyloid β plaques present 
in the AD brain act as chemoattractants for glial cells 
17-
20
. These extracellular aggregates will trigger the 
accumulation of activated microglia around their 
periphery, in turn inducing the release of pro-
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inflammatory cytokines, chemokines, reactive oxygen 
species, complement proteins and deleterious pro-
inflammatory mediators, such as some forms of 
prostaglandins 
21-24
. The functions and syntheses of all of 
these molecules are diverse, complex and beyond the scope 
of this introduction. For example, cytokines and 
chemokines regulate the intensity and duration of the 
immune response. Cytokine polymorphism is becoming a major 
focus of attention for determining its relationship to 
increased risk of developing AD 
25
. Prostaglandins (PGs), 
also produced by microglia, are active arachidonic acid 
metabolites that are rapidly degraded thus acting as local 
hormones. The key enzymes in the synthesis of s are 
cyclooxygenases (COX). The brain expresses COX-1 and COX-2 
under normal physiological conditions but COX-2 levels are 
dynamically regulated by pro-inflammatory signals, such as 
cytokines, and by physiological neuronal plasticity 
26
. 
Astrocytes are the most common cells in the brain and 
are involved in maintaining the functional integrity of 
synapses. Although astrocyte functions remain to be fully 
understood, it seems quite clear that they are co-
localized with pro-inflammatory molecules and microglia at 
the sites of aβ deposition 27;28. Astrocytes in the brain 
release chemokines that are able to modulate the 
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activation state of microglia through Nrf2-dependent 
antioxidant gene expression. As a consequence microglia 
synthesize more oxidant scavengers, such as glutathione. 
This will reduce the overall oxidative load disrupting the 
self propelled cycle of microglia activation, inflammation 
and its collateral damages 
29
. 
Neurons produce complement proteins, several 
cytokines (IL-1, IL-6, α and pentraxins, a family of 
acutephase proteins involved in activation of the 
complement system. Most interestingly, neurons were shown 
to activate microglia 
30;31. Indeed, aβ1-42-treated neuronal 
cells have the ability to bind microglia via CD14 
32
 
inducing the release of IL-6 
33
. It is also remarkable that 
treatment of neurons with D2, the major CNS prostaglandin, 
results in a phenotypic change that induces microglia 
activation producing a buildup of pro-inflammatory signals 
34
. In addition, studies with post mortem human brains show 
that COX-2 is overexpressed in neurons during the early 
stages of AD, prior to maximal activation of astrocytes 
and microglia 
35
. These studies suggest that in AD pro-
inflammatory responses might be initiated by neurons and 
followed by and enhanced by astrocytes and microglia. 
Indeed, different studies suggest that detection of 
inflammatory factors in cerebrospinal fluid is a good 
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indicator of the disease and a possible strategy for early 
diagnosis 
36;37
. 
The toxicity of inflammation is mostly mediated by 
generation of two forms of free radicals ( and reactive 
nitrogen species) released by microglia as a mechanism for 
attacking a noxious agent 
38;39
. Furthermore, the peroxidase 
activity of  also produces free radicals including 
superoxide 
40
. Free radicals are highly reactive species 
that induce deleterious alterations of protein structure 
and activate cell apoptosis 
41
. Unlike microglia, most 
cells are sensitive to oxidative stress and neurons are no 
exception. A means to avoid the formation of such radicals 
could involve a restrain of the inflammatory response. 
Interestingly, a highly toxic prostaglandin, 15d-PGJ2, 
inhibits NADH-ubiquinone reductase of the complex one of 
the mitochondrial respiratory chain, leading to the 
formation and accumulation of ROS 
42
, the release of 
cytochrome c from the mitochondria 
43
and cellular death 
through apoptosis 
44;45
. 
The ability to halt inflammation seems to be impaired 
in AD. The use of nonsteroidal anti-inflammatory drugs 
(NSAID) to prevent or treat AD is a hotly debated strategy 
45;45;46
. Most NSAIDs inhibit  and ideally should decrease 
the generation of prostaglandins and . Recent clinical 
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trials with NSAIDs were based on the hypothesis that these 
drugs could be preventive in the early but not advanced 
stages of the disorder. However, the data suggest that 
NSAIDs failed to fulfill the expectations of delaying 
memory loss. It is possible that massive use of NSAIDs is 
deleterious for the neurons, as these drugs modulate γ-
secretase, an enzyme involved in aβ formation 47. 
Furthermore, COX-2 activity could play an important role 
in memory, as it is involved in synaptic plasticity 
48;49
. 
Arachidonic signaling through the  pathways yields an 
enormous variety of products, some of them with pro-
survival others with pro-death effects. For instance, 
prostaglandins are known to be pro-inflammatory under 
certain conditions and anti-inflammatory under others 
(reviewed in 
50
). The dual role of prostaglandins is quite 
complex as a single prostaglandin can bind to multiple 
receptors. Accordingly, PGE2 can bind to four different 
membrane-bound receptors (EP1--4), each triggering 
different responses inside the cell. While EP1 and EP3 
activation is linked to neurotoxicity 
51;52
, EP4 activation 
has neuroprotective and anti-inflammatory effects 
53;54
. 
Likewise, two receptors (DP1 and DP2) were identified for 
PGD2. DP1 activation increases cAMP, activates protein 
kinase A and is linked to an anti-inflammatory response, 
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while DP2 activation increases the cellular influx of 
calcium and triggers a pro-inflammatory response (reviewed 
in 
55
). PGD2-mediated activation of DP1 was found to be 
neuroprotective while DP2 activation was neurotoxic 
56
. 
Besides binding to different receptors some 
prostaglandins, such as PGD2 and PGE2, are spontaneously 
metabolized by non-enzymatic dehydration to cyclopentenone 
prostaglandins, such as PGA2 and PGJ2, respectively. 
Cyclopentenone prostaglandins may have an anti-
inflammatory effect by inhibiting the NFκB pathway or a 
neurotoxic effect by inducing apoptosis (reviewed in 
57
). 
As suggested in the latter review „formation of 
cyclopentenone eicosanoids in the brain may represent a 
novel pathogenic mechanism, which contributes to many 
neurodegenerative conditions 
58
. 
Clearly, the effects of different prostaglandins are 
variable and may depend on factors such as intracellular 
concentrations, receptor types, cell types and timing of 
activation of downstream targets that participate in the 
inflammatory response. Rather than inhibiting , modulating 
the effects of  through more specific interference with 
their selective synthases and/or their receptors may be 
more effective, as prostaglandins can play different roles 
in recovery or degeneration. Much more needs to be learned 
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about the functions of inflammation in the normal and 
diseased CNS. The challenge resides in dissecting the dual 
nature of neuroinflammation as it has both positive and 
negative effects differing spatially and temporally in the 
CNS. 
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1.2. INFLAMMATION-DEPENDENT POST-TRANSLATIONAL 
MODIFICATIONS OF TAU 
1.2.1 TAU HYPERPHOSPHORYLATION IN ALZHEIMER’S 
DISEASE 
Tau is a microtubule-associated protein that 
stabilizes microtubules in a phosphorylation-dependent 
manner. Tau pathology appears to be closely related to the 
severity of dementia in AD. The pathological NFT in AD 
contain paired helical filaments (PHF) with 
hyperphosphorylated tau. PHF formation from tau molecules 
may follow several steps that involve tau phosphorylation, 
conformational changes and finally polymerization. 
Abnormal hyperphosphorylation of tau is responsible for 
its loss of biological activity, its resistance to 
degradation and is likely to be critical to NFT formation. 
Hyperphosphorylation of tau at pathologically relevant 
sites seems to precede NFT formation, to disrupt axonal 
integrity and to trigger neuronal loss 
59
. If indeed 
abnormal hyperphosphorylation facilitates tau assembly 
into PHF, it is of the utmost importance to identify 
kinases and phosphatases that contribute to tau 
hyperphosphorylation and also to understand what triggers 
their enzymatic activities. Since pro-inflammatory 
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conditions in the brain have been implicated in AD we will 
discuss recent evidence linking inflammation to tau 
hyperphosphorylation and NFT formation. 
A direct link between inflammation and tau 
phosphorylation was established in experiments showing 
that activation of microglia with  or  fragments induced 
neuronal tau phosphorylation in co-cultures with rat 
primary neocortical neurons 
60
. The microglia effects on 
tau phosphorylation were mimicked by directly treating the 
primary neurons with IL-1β. Microglia-induced tau 
phosphorylation appeared to be mediated by p38-MAPK, a 
proline-directed kinase. In other studies, treatment of 
rat hippocampal neurons with IL-6 induced anomalous tau 
hyperphosphorylation on epitopes dependent on proline-
directed kinase activity, including Cdk5 and p38-MAPK 
61
. -
induced inflammation in 3xTg-AD transgenic mice that 
harbor three mutant human genes (APPK670N; M671L, PS1M146V, and 
tauP301L) was also shown to exacerbate tau pathology 
62
. In 
these mice, inflammation-induced tau hyperphosphorylation 
was mediated by Cdk5. The latter is a kinase activated by 
binding to its membrane cofactor p35. During inflammation, 
the calcium-dependent cysteine protease calpain is 
activated leading to cleavage of p35 to p25, a 208-residue 
carboxyl-terminal fragment of p35. The p25 product is more 
  
 
15 
stable and has a higher affinity for Cdk5 than p35. 
Generation of the p25 fragment prolongs activation and 
mislocalization of Cdk5 resulting in hyperphosphorylation 
of atypical substrates, including tau 
63
. In the human 
brain, elevated levels of p25 correlate with AD. Together 
these studies support the view that one of the mechanisms 
inducing anomalous tau hyperphosphorylation may be 
initiated by inflammation and mediated by Cdk5 and/or p38-
MAPK. 
Inflammation was also shown to alter the activity of 
GSK3β, another proline-directed kinase postulated to play 
a role in the pathological hyperphosphorylation of tau. 
Treatment of HEK293/tau441 cells with nitric oxide donors 
induces tau phosphorylation at the S262 and S396/404 
pathological sites in a GSK3β-dependnt manner 64. 
GSK3βdependency was corroborated by an observed decrease 
in its Ser9 phosphorylation, which is required for kinase 
activation, and by preventing tau hyperphosphorylation by 
pretreating the cells with LiCl, a known GSK3β inhibitor 
65
. Co-expression of a triple FTDP-17 tau mutation with 
GSK3β in transgenic mice induced an earlier formation of 
PHF-like structures and a more rapid atrophy of 
hippocampal gyrus than in transgenic mice overexpressing 
GSK3β alone. These results support a synergy between the 
  
 
16 
two tau modifications, i.e. point mutations and 
hyperphosphorylation, and link tau hyperphosphorylation to 
GSK3β activity 66. Based on the studies described above, 
Cdk5, p38-MAPK and GSK3β are likely candidates for 
mediating the effects of inflammation on the pathological 
hyperphosphorylation of tau in AD. 
Since tau activity is regulated by its degree of 
phosphorylation and dephosphorylation it is also 
reasonable to investigate if deregulation of tau 
phosphorylation under pro-inflammatory conditions is 
caused by decreases in phosphatase activity. Phosphatases 
such as PP1, PP2A, PP2B and PP2C are known to reverse tau 
phosphorylation, with PP2A postulated to be the 
phosphatase that dephosphorylates most tau phosphorylation 
sites. A study addressing the activity of the different 
phosphatases demonstrated that PP2A accounts for 71% of 
tau dephosphorylation activity 
67
. Decreased methylation of 
the catalytic subunit of the PP2A complex leading to its 
inhibition was observed in the affected areas of AD brains 
68
. Interestingly, PP2A was shown to be a key regulator of 
JNK activity known to drive the expression of cytokines, 
such as IL-1β 69. A decrease in PP2A activity, such as 
identified in AD brains, may thus exacerbate the 
deleterious effects of inflammation on the brain, by 
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increasing cytokine synthesis. Overall, the studies 
discussed above support a role for inflammation in the 
process of NFT formation associated with AD, through 
activation of proline-directed kinases or inhibition of 
phosphatases and thus promoting the pathological 
hyperphosphorylation of tau. 
 
1.2.2 TAU CLEAVAGE IN ALZEHEIMER’S DISEASE  
a)Caspases 
Since 1988 
70
 it is well established that the core of 
insoluble PHFs contained proteolyticaly cleaved tau. It is 
now known that tau truncation is indeed an early event in 
the disease state that triggers the appearance of 
filamentous tau in NFTs in AD.
71
 Even though Aβ and the 
senile plaques are an early hallmark of AD, cognitive 
impairment is directly tied to the amount of 
neurofibrillary tangles inside neurons. AD brain filaments 
show a core of the microtubule-binding domain of tau and a 
small number of flanking sequences while the surface of 
the filament is coated with full length tau.  
The current hypothesis is that intracellular (in the 
ER, or endosomes) and extracellular Aβ deposits 
(protofibrils and oligomers) cause cellular apoptosis. 
Although the apoptosis characteristics of DNA cleavage 
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have not been demonstrated, the activation of cysteine 
aspartyl proteases (caspases) has been well established. 
The membrane (spectrin), cytosolic (intermediate 
filaments), and cytoskeletal proteins (tau) are all in 
vitro caspase substrates. Even though apoptosis per se is 
incomplete in neurodegeneration, apoptotic mechanisms are 
probably playing a role in neurodegeneration 
72
. 
In vitro studies demonstrated that after arachidonic 
stimulation, polymerization of full length and C-terminal 
cleaved tau forms filaments that are morphologically 
similar. In both cases the polymers resemble the unpaired 
straight filaments present in NFTs.  Interestingly, 
treatment of E18 rat primary cortical and hippocampal 
neurons with fibrillar Aβ peptides in the medium activates 
caspases and tau cleaved at Asp421 (TauΔ421) is detected 
by western blot analysis. This caspase cleavage of tau can 
partially be prevented when the cultures are pre-incubated 
with a potent caspase inhibitor 
73
. Treatment of 
hippocampal neurons with fibrillar Aβ induces neurite 
degeneration and complete collapse of microtubules only 
when tau is expressed in the cells. Tau depleted neurons 
show no signs of degeneration in the presence of Aβ, 
supporting a role for Tau in Aβ-induced neurodegeneration 
74
. This spectrum of in vitro and in vivo models strongly 
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asserts a direct link between the extra-cellular amyloid 
aggregation and the intra-cellular neurofibrillary tangle 
formation.  
The mechanism of tau aggregation and its toxicity is 
the source of an extensive array of studies. Wang et al. 
demonstrated in N2a cells that the sequentially cleaved N-
terminal and C-terminal tau protein is the seed for full 
length tau aggregation. N-terminal cleavage of tau induces 
a change of conformation (going from unfolded protein to 
β-sheet structure), making the N-terminal cleaved tau more 
susceptible to C-terminal cleavage. The consequence of the 
last cleavage induces the aggregation of full length tau 
into filamentous structures. In relation to aggregation, 
the phosphorylation state of tau seems secondary to its 
cleavage. Also interesting is the direct link between the 
aggregate buildup and the level of cell toxicity. Although 
the C-terminal proteases of tau are still unidentified, 
they are of particular interest to alleviate the 
generation of amyloidogenic fragments and their deadly 
aggregation 
75
.  
In vitro cleavage assays of full length tau in the 
presence of various caspases show that tau is more 
susceptible to the protease activity of executioner 
caspases (-3, -7) than initiator caspases (-1, -4, -5, -8, 
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-10). The resulting C-terminal product is 45.9kDa and a 
small 2kDa fragment. Interestingly TauΔ421 seems more 
prone to adopt MC1 conformation than full length tau. The 
MC1 conformation is the result of the folding of the N-
terminal segment of Tau which interacts with the 
microtubule binding region. MC1 is a distinct conformation 
of Tau in AD, that precedes PHFs formation and is detected 
in Braak stage I and II
76
. Its detection in structurally 
intact axons hints toward a prepathological cleavage 
event. In vitro aggregation assays indicate a faster rate 
of oligomerization for TauΔ421 as well as a seeding effect 
for the full length Tau nucleation. In AD hippocampus, 
immunohistochemical staining for TauΔ421 showed widespread 
labeling within the CA1 region. This distribution 
correlates inversely with cognitive function and 
colocalizes with intraneuronal and extraneuronal Aβ 
deposits. The treatment of E18 rat primary cortical 
neurons with Aβ1-42 triggers the cleavage of tau 
detectable within 6 hrs post incubation suggesting that 
caspase cleavage of tau was initiated by Aβ1-42 
accumulation.
77
 
Double labeling of AD and control hippocampal 
sections for cleaved fodrin (a cytoskeletal protein and 
calpain-caspase substrate) and PHF showed a clear co-
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localization of these markers. Quantitative analysis 
showed that as the extent of NFT formation increased, 
there was a significant corresponding increase in cleaved 
fodrin immunolabeling. This provides evidence that there 
is an association between NFT formation and activation of 
apoptotic pathways in AD
78
. Furthermore tau was shown to be 
an in vitro substrate for Caspase-3. It was also 
demonstrated in rat hippocampal cells that TauΔ421 is a 
potent effector of apoptosis, implying that tau may be 
involved in the self-propagating processes suggested to 
drive neurodegeneration 
79;80
.  
TauΔ421 is also a common feature of other 
Tauopathies. Indeed cleaved tau is detected not only in AD 
but also in Pick‟s disease, supranuclear palsy, 
corticobasal degeneration, dementia with Lewy bodies. 
Notably, these neurodegenerative diseases are not 
characterized by extracellular Aβ accumulation.  
The presence of hyperphosphorylated and cleaved tau 
together suggest that common initiating events other than 
extra-cellular Aβ accumulation leads to the activation of 
caspase and cleavage of cytoskeletal proteins 
81
. 
Phosphorylation precedes cleavage in tangle evolution and 
it seems that phosphorylation at S422 prevents caspase 
cleavage some time during the progression of AD. Indeed in 
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vitro pseudophosphorylation of tau at S422 makes tau more 
resistant to caspase-3 proteolysis and to other tau 
cleavages as the pathology advances, suggesting a 
potential protective mechanism that could inhibit  
cleavage in vivo.
82
 
The two main activation pathways for apoptosis are 
(1) via death-receptor and caspase 8 initiation and (2) 
through the mitochondrial pathway and caspase 9 
initiation. The two pathways collude with the pro-caspase 
3 cleavage and triggering of the caspase cascade. 
Immuhistochemistry of AD and control brains showed a 
colocalization of Casp-8 and NFT. Rohn et al 
83
 however 
demonstrated, with a caspase-9 cleaved specific antibody, 
the “labeling of neurons in the hippocampus and enthorinal 
cortex from severe AD brains, as well as oxidized DNA/RNA 
damages”. The colocalization of activated casp-8 and casp-
9 suggests that both apoptotic pathways occur within the 
same neurons of AD brains. Remarkably there is a negative 
correlation between casp-9 activation and tangle formation 
suggesting that casp-9 precedes tangle formation. Aβ could 
lead to death-receptor apoptosis, while oxidative stress, 
due to aging or disease, induces mitochondrial damage and 
casp-9 activation. These two pathways result in over-
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activation of casp-3 leading to tau cleavage as well as to 
its pathological aggregation. 
 
b) Calpain 
Normal tau isolated from human brains as well as 
recombinant tau isoforms are in vitro substrates for 
calpain 
84
 and in AD calpain I is highly activated.
85
  In 
vitro experiments with tau isolated from human tissues 
demonstrated that the degree of tau phosphorylation has no 
impact on its affinity for calpain. In addition, the tau 
fragments generated were similar to those isolated from AD 
brain extracts. However, the aggregation of tau into PHF 
makes tau resistant to calpain digestion suggesting that 
the cleavage of tau by calpain precedes its aggregation. 
86
 
For a long time it has been speculated that following 
injuries, neuronal cell death was the result of necrosis, 
characterized by massive ion influx, mitochondrial 
swelling, cell swelling, non-specific DNA breakage in the 
nuclei and plasma membrane rupture. More recent data 
showed that in chronic neurodegenerative diseases such as 
Huntington‟s disease, AD and ALS, apoptosis and necrosis 
are both occurring. The key enzyme of the necrotic 
neuronal death pathway is calpain, a pro-enzyme 
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heterodimer activated autocatalytically and by 
intracellular Ca
2+
.   
The key enzyme in the caspase cascade of apoptotic 
neuronal death is caspase 3, existing as a pro-enzyme and 
being activated by caspase 8- or caspase 9-mediated 
catalysis. Calpain and caspase 3 mediate only partial 
cleavage and not complete cleavage of their substrates. It 
is interesting to notice that the two death pathways, 
necrosis involving calpain and apoptosis involving caspase 
3, are in many instances interconnected. For example in 
certain cell types, such as in cerebellar granule neurons, 
calpain is activated during apoptosis. Calpain and caspase 
3 share the same substrates which are mostly cytoskeleton 
related proteins. Although the cleavage sites of the 
substrates differ, the resulting fragments are very close 
in size. Considering that the two cell deaths pathways are 
both activated in the case of neurodegenerative disorders, 
it might be of interest to try to prevent both phenomena 
to preserve the cells 
87
. Interestingly, testosterone 
prevents the calpain cleavage of tau but not its caspase 
cleavage, while estrogen does the reverse in rat 
hippocampal neurons treated with Aβ fragments. This 
reinforces the parallel activation of both pathways that 
include the two proteases, calpain and caspase 3 
88
. 
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c) Cathepsin D 
In 1997 Kennessey et al 
89
 demonstrated that different 
isoforms of human tau are degraded by cathepsin D in 
vitro, and that cleavage by cathepsin D could occur at 
neutral pH. In AD, cathepsin D level is elevated in 
disease vulnerable neurons, and amyloid deposition as well 
as endosomal-lysosomal changes are early events in late-
onset AD 
90
. Gallyas-Braak silver staining of AD neurons 
and normal neurons, reveals intracellular granules 
containing altered tau 
91
. This suggests that lysosomes and 
their aspartic-protease cathepsin D may normally degrade 
altered tau 
92
. Disruption of lysosomes induces release of 
cathepsins to the cytoplasm. In rat hippocampal slices, 
lysosomal disruption results in the hyperphosphorylation 
and fragmentation of tau that assembles into structures 
having the appearance, size, and epitope of early-stage 
neurofibrillary tangles 
93
. These events could be partially 
prevented by cathepsin D inhibitors.  
Cathepsin D is rapidly translocated from the lysosome 
to the cytoplasm during apoptosis linked to ROS, 
supposedly the consequence of lipid peroxidation in 
intracellular membranes 
94
. Once the lysosomal membrane is 
damage cathepsin D leaks into the cytoplasm. Since there 
is no known endogenous cytoplasmic inhibitor, cathepsin D 
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that is very stable at cytoplasmic pH, activates the 
effector caspase-3 
95
. Furthermore, cathepsin D release 
into the cytoplasm precedes the relocation of cytochrome c 
during apoptosis induced by oxidative stress, suggesting 
once again the potentiating apoptotic activity of 
cathepsin D 
96
.  
   
d) Controversy surrounding tau ubiquitination and 
degradation by the proteasome. 
There is little doubt that hyperphosphorylated tau is a 
major component of NFT. Whether NFT tau is ubiquitinated 
and degraded in vivo by the ubiquitin-proteasome pathway 
remains controversial. One could speculate that the 
decrease in proteasome activity observed in AD brain 
regions with severe degeneration 
97
 may contribute to the 
accumulation of ubiquitinated tau in NFT.  
At least two mechanisms relevant to AD were postulated 
to inhibit proteasome activity. One of the mechanisms is 
associated with frameshift mutants of ubiquitin B (UbB+1) 
found to be co-localized with NFT and senile plaques in 
the cerebral cortex of patients with sporadic AD 
98
. A 
single dinucleotide deletion (GA) in the first GAGAG motif 
of UbB mRNA produces UbB+1, which lacks the C-terminal 
glycine, an amino acid critical for ubiquitination. UbB+1 
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molecules may impair degradation of ubiquitinated proteins 
by competing with wildtype ubiquitin for the interaction 
with the 26S proteasome and thus lead to neuronal cell 
death 
99;100
. The other mechanism leading to proteasome 
inhibition involves the direct binding of PHFs to the 
proteasome thus impairing its activity 
101
. 
The finding that proteasome activity is decreased in AD 
brains does not necessarily imply that the proteasome is 
involved in the in vivo degradation of tau. A 
tau/proteasome link remains questionable. On the one hand, 
tau was shown to be degraded by the proteasome in vitro 
102;103
, in cell cultures 
104-107
, in rat brain cortex extracts 
108
 and in 3Tg-AD transgenic mice 
109
. Tau degradation by 
the proteasome is postulated to require its K63-
polyubiquitinated form to interact with the sequestosome 
1/p62, a putative „shuttling‟ partner for some proteasome 
substrates 
110
. On the other hand, tau degradation was 
shown to be independent of proteasome activity in rat 
primary hippocampal neurons 
111
, human neuroblastoma SH-
SY5Y cells 
112;113
 and in Drosophila harboring a temperature-
sensitive mutant allele of the 20S proteasome 
114
. The 
reasons for this discrepancy are unclear but might be 
related to the different experimental protocols and model 
systems involved in the various studies. 
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While the controversy surrounding the in vivo 
degradation of tau by the proteasome remains unresolved, 
other studies focused on the pathologic aspect of a 
putative tau/proteasome link. It is clear that tau is 
hyperphosphorylated prior to its aggregation in PHFs, 
which then lead to NFT formation. Hyperphosphorylated tau 
is recognized and ubiquitinated by the Ubox protein CHIP 
115-117
. Interestingly, CHIP levels in human AD brains were 
found to be inversely proportional to insoluble tau 
accumulation 
118
. In a JNPL3 mouse tauopathy model, CHIP 
levels were low in the spinal cord, the most prominent 
region exhibiting tau inclusions and neuronal loss in 
these mice. In addition, mice lacking CHIP exhibited the 
highest levels of insoluble tau in the brain 
119
. These 
results suggest that CHIP delays the formation of tau 
aggregates. CHIP is a co-chaperone with intrinsic 
ubiquitin ligase activity, a property that allows its 
chaperone function to switch from protein folding to 
protein degradation 
120
. CHIP is activated after binding 
with Hsc/Hsp70, forming a complex that selectively 
ubiquitinates hyperphosphorylated tau in conjunction with 
UbcH5B 
121
. Interestingly, PHF tau was found to be 
ubiquitinated at its microtubule binding domain, 
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suggesting that tau ubiquitination may be an early 
pathological event in the AD cascade 
122
.  
Sumolation may be another tau modification relevant to 
its pathogenic role. Sumolation is a post-translational 
modification consisting of the addition of „small 
ubiquitin-like modifiers‟ to lysine residues of target 
proteins, which under certain conditions leads to a 
partial proteasome digestion and to a change in protein 
function 
123
. Tau sumolation was found to be up-regulated 
in cells treated with phosphatase inhibitors or 
microtubule depolymerizing agents 
124
.  
Overall these studies highlight challenges for future 
research to understand the requirements for achieving the 
proper balance between tau stability and degradation to 
prevent its pathological aggregation into PHFs leading to 
NFT formation. 
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1.3. OVERALL RELEVANCE 
   There is no doubt that chronic inflammation is a 
critical factor in the pathogenesis of neurodegenerative 
disorders, such as Alzheimer‟s disease (AD). Increases in 
cyclooxygenase-2 (COX-2) levels in neurons and glia 
(astrocytes and microglia) are observed in these disorders 
associated with chronic inflammation. However, there is a 
profound gap in our understanding of how pro-inflammatory 
cyclooxygenases and their prostaglandin products redirect 
cellular events to promote neurodegeneration. The main 
goal of our studies is to address this crucial omission. 
We elucidate some of the downstream mechanisms by which 
COX-2 products, in particular cyclopentenone prostaglandin 
J2, cause neuronal injury.  
   Our studies underscore a synergy between proteasome 
deficiency and inflammation in triggering 
neurodegeneration. Cells must constantly rely on 
proteasome activity to remove abnormal proteins produced 
under pro-inflammatory and other stress conditions. 
Impairment of proteasome function will exacerbate the 
deleterious effects of inflammation, and activate pathways 
leading to neurodegeneration. Elucidation of mechanisms 
that cause pathological protein aggregation will be 
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opening up new and important possible targets for 
treatment of neurodegenerative disorders, such as AD, that 
are associated with chronic inflammation and protein 
degradation. 
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2.1. ABSTRACT 
Neurofibrillary tangles (NFT) are a hallmark of 
Alzheimer‟s disease (AD). The major NFT component is tau, 
which is truncated at Asp421 (tau), hyperphosphorylated, 
and aggregates into insoluble paired helical filaments. AD 
brains also exhibit inflammation manifested by activated 
astrocytes and microglia, which produce cytotoxic agents 
among them prostaglandins. We treated human neuroblastoma 
cells with prostaglandin J2 (PGJ2), a highly reactive 
lipid electrophile that covalently binds free sulfhydryls 
of glutathione and cysteine residues in cellular proteins 
forming Michael adducts. Clearly, the initial event 
observed upon PGJ2-treatment was the build-up of 
ubiquitinated proteins. The onset of apoptosis followed 
manifested by caspase activation and caspase-mediated 
proteolysis of tau, generating tau (Asp421). Cathepsin 
inhibition stabilized tau suggesting its lysosomal 
clearance. Upon PGJ2-treatment tau accumulated in a large 
perinuclear aggregate. Tau was also observed in PGJ2-
treated rat primary neuronal cultures. Overall, our data 
suggest that products of inflammation such as PGJ2 promote 
an abnormal build-up of ubiquitinated proteins that, if 
not cleared, launches caspase-mediated proteolysis that 
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generates tau. This may indicate a new inflammation-
mediated pathway for tau pathology in AD.  
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2.2. INTRODUCTION 
 Inflammation is implicated in Alzheimer‟s disease (AD) 
125
. A recent study with P301S mutant human tau transgenic 
mice established that hippocampal synaptic pathology and 
microgliosis could be the earliest manifestations of 
neurodegeneration related to tauopathies 
126
. Prominent 
microglial activation was shown to precede tangle 
formation and immunosuppression of young P301S Tg mice 
diminished tau pathology and increased lifespan. It was 
proposed that neuroinflammation is linked to early 
progression of tauopathies 
127
.  
Activated microglia and astrocytes produce a variety of 
agents, among them prostaglandins 
128
. The major 
prostaglandin produced in the CNS is prostaglandin D2 
(PGD2) 
129;130
. PGD2 levels were found to be significantly 
increased in the frontal cortex of AD patients compared to 
age matched controls 
131
. PGD2 is produced by two distinct 
types of prostaglandin D2 synthases (PGDS): (1) the 
lipocalin enzyme (L-PGDS) and (2) the hematopoietic enzyme 
(H-PGDS) 
132
. In addition, PGD2 binds to G protein-coupled 
seven transmembrane receptors, DP1 and DP2 
133
, which are 
robustly expressed in the hippocampus and cerebral cortex 
134
. In AD patients and in Tg2576 mice, a well established 
AD model, the levels of H-PGDS and DP1 were found to be 
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selectively up-regulated in microglia and astrocytes 
within senile plaques 
135
. Based on these results it was 
suggested that PGD2 acts as a mediator of plaque 
associated inflammation in the AD brain 
136
. Similarly, L-
PGDS which is one of the most abundant CSF proteins 
produced in the brain, was localized in amyloid plaques in 
both AD patients and Tg2576 mice 
137
. Secreted L-PGDS in 
the CSF has a dual function: it increases CSF-PGD2 levels 
138
 and also acts as a lipophilic-ligand carrier 
139
. L-PGDS 
was found to bind A monomers and prevent A aggregation, 
suggesting that L-PGDS is a major A chaperone and 
disruption of this function could be related to the onset 
and progression of AD 
140
.  
 PGD2 exerts both neuroprotective and neurotoxic effects 
through its binding to DP1 and DP2 receptors, respectively 
141
. PGD2 is very short lived and readily undergoes in vivo 
and in vitro non-enzymatic dehydration to generate the 
biologically active cyclopentenone J2 prostaglandins, 
which include PGJ2, 12-PGJ2 and 15-deoxy-12,14-PGJ2 
(15d-PGJ2) 
142
.  
Unlike most other classes of prostaglandins, 
cyclopentenone prostaglandins like PGJ2 have a 
cyclopentenone
 
ring with reactive ,-unsaturated carbonyl 
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groups that form covalent Michael
 
adducts with nucleophiles 
such as free sulfhydryls in cysteine
 
residues of 
glutathione and cellular proteins 
143
. Just like serine, 
threonine and tyrosine phosphorylation is crucial for 
various signal transduction pathways, it has become 
recently clear that a highly conserved redox reaction of 
cysteine thiols in proteins provides post-translational 
means for regulating redox signaling 
144
. S-nitrosylation 
of cysteine thiols by nitric oxide was first discovered, 
followed by the more recently revealed S-alkylation by 
electrophiles (electron deficient carbon centers). 
Electrophile binding by endogenous metabolites such as 
PGJ2 is currently regarded as playing a crucial role in 
determining whether neurons will live or die 
145
. 
We focus on PGJ2 because it is potently neurotoxic and a 
highly reactive product of inflammation. A recent review 
suggested that “formation of cyclopentenone eicosanoids 
[such as PGJ2] in the brain may represent a novel 
pathogenic mechanism that contributes to many 
neurodegenerative conditions” 146. Because of their high 
reactivity with thiol-containing intracellular compounds 
like glutathione or thiol-containing proteins via Michael 
addition, any attempt to measure PGJ2 levels in human 
tissues or fluids will be highly inaccurate and will not 
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reflect its biological activity 
147
. Similar to PGJ2, 
nitric oxide has a half life of just a few seconds, and 
yet is well accepted as a major signaling molecule in 
neurons and in the immune system 
148
. The same can be said 
for PGJ2, i.e. that it is a major signaling 
molecule/oxidative stress agent.  
Here we show that the lipid electrophile PGJ2 induces 
tau cleavage at Asp421 in a time- and dose-dependent 
manner in human neuroblastoma SK-N-SH cells. PGJ2-induced 
tau cleavage is mediated by caspases, which are activated 
upon cell treatment with PGJ2. In addition, we demonstrate 
that the abnormal build-up of ubiquitinated proteins 
induced by PGJ2 clearly preceded caspase activation, 
caspase-mediated tau cleavage and apoptosis. PGJ2 
modulation of tau cleavage was also observed in rat 
primary neuronal cultures. These results demonstrate that 
products of inflammation such as PGJ2 have a bifunctional 
effect on intracellular protein turnover. They impair the 
ubiquitin/proteasome pathway leading to the abnormal 
build-up of ubiquitinated proteins that, if not cleared, 
activates caspase-mediated proteolysis responsible for 
generating tau that could serve as a seed for cytotoxic 
protein aggregation. This abnormal and sequential build-up 
of intracellular ubiquitinated proteins followed by the 
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formation of aggregation prone truncated proteins, such as 
tau, could be a major factor in the progression of AD 
neurodegeneration. 
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2.3 MATERIALS AND METHODS 
 2.3.1 MATERIALS  
PGJ2, ciglitazone and BADGE were from Cayman Chemical 
(Ann Arbor, MI). Protease inhibitors: caspase irreversible 
inhibitors (2M) for individual caspases 1 through 6, 8 
through 10 and 13, the pan caspase inhibitor (Z-VAD-FMK), 
which inhibits all known caspases, and the negative 
control Z-FA-FMK (FMK) were from BioVision, CA. Caspase 
inhibitor I, which inhibits all caspases and is the same 
as the pan caspase inhibitor, calpeptin (Z-Leu-Nleu-CHO), 
calpain inhibitor I (N-Acetyl-Leu-Leu-Nle-CHO), calpain 
inhibitor III (Z-Val-Phe-CHO), and Pepstatin A (Iva-Val-
Val-Sta-Ala-Sta) were from Calbiochem (San Diego, CA). 
Calpain inhibitor (Z-Leu-Leu-CHO) was from BioMol 
(Plymouth Meeting, PA), PSI [Z-Ile-Glu(OtBu)-Ala-Leu-CHO] 
from Peptides International Inc. (Louisville, KY), and NAC 
(N-Acetyl-Cysteine) from Sigma-Aldrich, St. Louis, MO. 
Primary antibodies: Tau C3 (mouse monoclonal, tau cleaved 
at Asp421) 1:500 from Covance (Emeryville, CA), Tau clone 
5 (mouse monoclonal) 1:1000 courtesy Dr. L. Binder 
(Northwestern University, Chicago, Il), TauY9 (rabbit 
polyclonal) 1:1000 from BioMol (Plymouth Meeting, PA), pan 
tau clone 13 (mouse monoclonal) 1:1000 from Santa-Cruz 
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(Santa Cruz, CA), mouse monoclonal anti--tubulin (1:2,000, 
clone GTU-88) from Sigma-Aldrich, rabbit polyclonal anti-
ubiquitinated proteins (1:1,500) from Dako Cytomation 
(Carpinteria, CA), anti-cleaved PARP (1:1000 clone 19F4) 
from Cell Signaling Tech (Danvers, MA),  anti-hsp90(86) 
(1;2000) from Affinity Bioreagent Inc., Golden, CO. The 
respective secondary antibodies with fluorophores (1:50) 
were from Jackson ImmunoResearch Laboratories, Inc. (West 
Grove, PA). TO-PRO-3 iodide (nuclear staining) was from 
Invitrogen (Carslbad, CA). 
 2.3.2 CELL CULTURES  
SK-N-SH cells are a human neuroblastoma cell line 
derived from peripheral tissue 
149
. The cells are 
maintained at 37
oC in MEM with Earle‟s salts containing 5% 
normal fetal bovine serum, 2mM L-glutamine, 1mM sodium 
pyruvate, 0.4% MEM vitamins, 0.4% MEM nonessential amino 
acids, and 100 units/ml penicillin, 100 µg/ml streptomycin 
in 5% CO2. 
Rat E18 cortical neuronal cultures were from Neuromics 
(Edina, MN). The cells were maintained at 37°C, in 5% CO2, 
in neurobasal media supplemented with 2% B27 and 0.5mM 
glutamine (all from Invitrogen) and half of the medium was 
changed every 3 days. 
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 2.3.3 CELL TREATMENTS 
Cell cultures were treated for the indicated times with 
vehicle (DMSO, dimethyl sulfoxide) or with different 
concentrations of PGJ2 in DMSO added directly to serum-
containing medium. The final DMSO concentration in the 
medium was 0.5%. At the end of the incubation, all 
cultures were washed twice with phosphate buffered saline 
(PBS) and processed for the different assays as described 
below. Cell washes removed unattached cells, therefore 
subsequent assays were performed on adherent cells only.
 2.3.4 WESTERN BLOTTING 
Western blot analysis was carried out by SDS-PAGE on 8% 
or 10% polyacrylamide gels. After treatment cells were 
rinsed twice with PBS and were harvested by gently 
scraping into ice-cold homogenization buffer [20mM Tris-
HCl, pH 7.5, 137mM NaCl, 1mM EGTA, 2.5mM Na4P2O7 , 1mM 
glycerophosphate, 50mM NaF, 1mM PMSF, 1% NP40, 1mM Na3VO4 , 
1% Glycerol and protease inhibitor cocktail (Sigma-
Aldrich)]. Samples were boiled for 5-min in Laemmli buffer 
and loaded onto gels (30-50g of protein/lane). Following 
electrophoresis, proteins were transferred to an 
Immobilon-P membrane (Millipore, Bedford, MA). The 
membrane was probed with the respective antibodies and 
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antigens were visualized by a chemiluminescent horseradish 
peroxidase method with the ECL reagent. As a control for 
protein loading the western blots were probed for actin 
[mouse monoclonal anti-actin (1:2,500, clone AC-20) from 
Sigma-Aldrich]. Semi-quantitative analysis of protein 
detection was done by image analysis with the ImageJ 
program (Rasband, W.S., ImageJ, U. S. NIH, Maryland, 
http://rsb.info.nih.gov/ij/, 1997-2006).  
 2.3.5 CELL VIABILITY 
 Cell survival was assessed with the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
(MTT) assay as described in 
150
.  
 2.3.6 CASPASE ACTIVITY ASSAYS  
 Caspase screening assays (for caspases 2, 3, 8 and 9) 
and caspase 3 assays were carried out with ApoAlert 
caspase kits (plates) from ClonTech (Mountain View, CA) 
following manufacturer‟s specifications.  
 2.3.7 SUBCELLULAR FRACTIONATION 
 After treatment SK-N-SH cells in 10cm dishes (4.5 x 10
5
 
cells/ml) were rinsed twice with PBS. Cells were harvested 
by gently rocking the dishes with 2ml of pre-warm (37°C) 
cell dissociation solution (Sigma-Aldrich) for 10min and 
packing the cells by centrifugation at 500Xg for three 
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min. The cell pellet was then lysed and the separation of 
enriched nuclear and cytoplasmic proteins was performed 
with a nuclear and cytoplasmic kit (NE-PER from PIERCE. 
Rockford, IL). After removing the soluble cytoplasmic and 
enriched nuclear extracts, the remaining pellet fraction 
was re-suspended in denaturing buffer (0.01M Tris-EDTA pH 
7.5, 2% SDS). 
 2.3.8 IMMUNOFLUORESCENCE  
 After treatment cells were rinsed with PBS, fixed for 
15min at 37°C in 2% formaldehyde in media, quenched with 
50mM NH4Cl/PBS for 20min, permeabilized with 0.1% 
saponin/PBS, blocked with 2% BSA/PBS, and incubated with 
the antibodies listed in each figure. Slides were mounted 
with Vectashield mounting medium hard set for 
immunofluorescence (Vector Laboratories, Inc., Burlingame, 
CA). Cell staining was visualized with Leica TCS SP2 
confocal microscope (Leica microsystems, Exton, PA). TO-
PRO-3 iodide (Invitrogen, Carslbad, CA) was used for 
nuclear staining. 
 2.3.9 PROTEIN CONCENTRATION  
  was determined with the bicinchoninic acid assay kit 
(Pierce, Rockford, IL) or the Bradford Assay (Bio-Rad, 
Hercules, CA).  
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2.3.10 STATISTICAL ANALYSIS 
statistical significance was estimated using one-way 
ANOVA (Tukey-Kramer multiple comparison test) or the 
unpaired “t” test with the Instat 2.0, Graphpad Software 
(San Diego, Ca). 
 
 
  
 
46 
2.4. RESULTS 
2.4.1 PGJ2 INDUCES ACCUMULATION OF UBIQUITINATED 
PROTEINS, TAU CLEAVAGE AND APOPTOSIS IN A DOSE 
DEPENDENT MANNER - Tau cleavage is an early event in AD 
tangle pathology 
151
. Furthermore, microglia activation was 
shown to precede tangle formation in the P301S tauopathy 
mouse model 
152
. We thus determined the effect of the 
product of inflammation PGJ2 on tau cleavage in human SK-
N-SH neuroblastoma cells. We assessed tau immunoreactivity 
in human neuroblastoma SK-N-SH cells with two monoclonal 
antibodies: tauC3 (epitope a.a. 412-421), which is 
specific for tau cleaved at Asp421 (Fig. 1A), and tau13 
(Fig. 1E, pan tau, epitope a.a. 2-18), which detects all 
tau isoforms of human origin. Tau C3 detected two major 
bands with an approximately molecular mass of ~60kDa (tau 
FL, full length) and ~44kDa (tau, tau cleaved at Asp421), 
while pan tau reacted with all tau isoforms as well as 
with tau. Equal protein loading was demonstrated by 
probing the blots with the anti-actin antibody (Fig. 1D).  
It is clear that the levels of tau increased in a 
concentration-dependent manner (Fig. 1A, E and G) reaching 
a peak at 20M PGJ2 after 16h of treatment (Fig. 1A, 
boxed). The tau peak coincided with a peak in apoptosis 
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assessed by PARP [poly (ADP-ribose) polymerase] cleavage 
(Fig. 1B and G) and with a ~53% decrease in cell survival 
assessed with the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide] assay (Fig. 1F). Notably, 
the highest levels of ubiquitinated proteins were observed 
in cells treated with lower concentrations of PGJ2 (10M). 
These results indicate that the production of tau is 
synchronized with the cell death pathway but trails the 
build-up of ubiquitinated proteins. 
 2.4.2 PGJ2 INDUCES ACCUMULATION OF UBIQUITINATED 
PROTEINS, TAU CLEAVAGE AND APOPTOSIS IN A TIME 
DEPENDENT MANNER - To establish the time-dependency of 
the PGJ2 effect on tau we incubated SK-N-SH cells with 
20M PGJ2 for 2h, 4h, 8h, 16h and 20h. Just like PARP 
cleavage (Fig. 2B and G), an indicator of apoptosis, tau 
was detected 16h post PGJ2- treatment (Fig. 2A, E and G). 
At this time point a significant decrease (~33%) in cell 
survival assessed with the MTT assay was also observed 
(Fig. 2F). This remarkable coincidence of tau and PARP 
cleavage indicates that Δtau is associated with the onset 
of apoptosis.  
 The accumulation of ubiquitinated proteins was detected 
2h after the PGJ2 treatment and reached a peak at 4h post-
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treatment (Fig. 2C and G). Clearly, the abnormal 
accumulation of ubiquitinated proteins precedes the onset 
of apoptosis and the generation of the stable Δtau and 
cleaved PARP, suggesting that if the cell cannot clear the 
overwhelming build-up of ubiquitinated proteins induces by 
PGJ2 it launches caspase-mediated proteolysis.  
 2.4.3 IN SK-N-SH CELLS PGJ2-TREATMENT ACTIVATES 
CASPASES WHICH IN TURN MEDIATE TAU CLEAVAGE - Since 
tau coincided with the onset of apoptosis we investigated 
if PGJ2 activates intracellular caspases. Initially, we 
run a caspase screening assay and established that 
treatment of SK-N-SH cells with 20M PGJ2 for 16h, 
significantly (p≤0.014, T test) activated all caspases 
tested, i.e. initiator caspases  (CASP2, CASP8 and CASP9) 
as well as the effector caspase 3, albeit different levels 
of activation were observed (Fig. 3A). Not surprisingly, 
caspase 3 showed the greatest activation (~20-fold) upon 
PGJ2-treatment, since it is an effector caspase. Following 
8h of treatment with 20M PGJ2, caspase 3 activity was 
significantly higher than in control (p<0.001, asterisks) 
and reached a peak (24-fold increase) by 16h post-
treatment. The peak in caspase 3 activity coincides with 
the peak in PARP cleavage, a known substrate for this 
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caspase, and tau peak supporting the view that tau is 
also a substrate for caspase 3. 
 In SK-N-SH cells tau cleavage induced by 16h of 
treatment with 20M PGJ2 (Fig. 4A, boxed lanes 2 and 10) 
was attenuated by pre-treatment with specific irreversible 
inhibitors (2µM) for individual caspases 1 through 6, 8 
through 10 and 13 (Fig. 4A, lanes 3-8 and 11-14). The pan 
caspase inhibitor, which inhibits all known caspases, also 
lessened the levels of tau (Fig. 4A, lane 15). The 
negative control Z-FA-FMK (FMK) did not affect full length 
tau (Fig. 4A, lane 16). Overall, these results clearly 
indicate that PGJ2-induced tau cleavage is caspase-
mediated.  
2.4.4 PHARMACOLOGICAL MANIPULATIONS OF TAU 
CLEAVAGE IN SK-N-SH CELLS - There are no specific 
prostaglandin synthases leading to PGJ2 production and no 
specific PGJ2 receptors have yet been identified 
153
. 
However, PGJ2 can act via the intranuclear receptor PPAR 
(peroxisome proliferator-activated receptor ) 154. To test 
if tau is induced by PPAR activation, we treated SK-N-SH 
cells with ciglitazone a bone fide PPAR ligand. As shown 
in Fig. 5A (lane 7) ciglitazone did not induce tau 
cleavage and the PPAR antagonist BADGE (bisphenol A 
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diglycidyl ether) failed to prevent PGJ2-induced tau 
(Fig. 5A, compare boxed lane 2 with lane 3) showing that 
PPAR does not mediate this PGJ2 effect on tau.  
Besides acting through receptors, PGJ2 can exert its 
action by covalently binding to free sulfhydryl groups on 
cysteines in glutathione and cellular proteins 
155
. N-
acetyl-cysteine (NAC) exhibits direct and indirect 
antioxidant properties and binds to electrophilic
 
groups 
156
. We thus tested if NAC prevented PGJ2 cleavage of tau. 
As seen in Fig. 5B (lane 6), NAC totally prevented the 
formation of tau. 
 Since PGJ2 is known to inhibit proteasome activity in 
cells 
157
 we investigated whether a proteasome inhibitor 
[PSI, N-benzyloxycarbonyl-Ile-Glu(O-t-butyl)-Ala-leucinal] 
would mimic the PGJ2 effect on tau. As shown in Fig. 5B 
(lanes 4 and 5) PSI did not increase the levels of tau. 
Neither did the calpain inhibitor Z-LL-CHO (Fig. 5B, lane 
3). 
 We also investigated if inhibitors of other 
intracellular proteases prevented tau cleavage by PGJ2 in 
SK-N-SH cells. Four different calpain inhibitors (Fig. 6A) 
and the general cathepsin inhibitor pepstatin (Fig. 6B) 
failed to abrogate PGJ2-induced tau. In fact, we observed 
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the highest levels of tau in cells co-treated with 
caspase inhibitor 1 and pepstatin prior to PGJ2 (Fig. 6B, 
boxed lane 3). These results mimic what was observed, to a 
lesser extent, with PGJ2 in conjunction with 20M caspase 
inhibitor 1 (Fig. 5A, lane 4). Caspase inhibitor 1, Z-VAD-
FMK, inhibits all caspases. However, it was previously 
demonstrated that caspase inhibitors with fluoromethyl 
ketones (FMK) also reduce the activity of lysosomal 
cathepsins 
158
.  These data indicate that caspase 
inhibitors exert a bifunctional, concentration-dependent 
effect on tau cleavage: low concentrations (2M) diminish 
tau, while high concentrations (20M) increase tau. The 
latter effect may indicate that once formed, tau is 
removed by lysosomal cathepsins, which are also inhibited 
by the higher (20M) caspase inhibitor 1 concentrations. A 
similar effect was not observed on PARP, as 20M caspase 
inhibitor 1 prevented PARP cleavage (Fig. 5A, middle 
panel, lane 4).  
 2.4.5 UPON TREATMENT OF SK-N-SH CELLS WITH PGJ2 
TAU IS ASSOCIATED WITH AN ENRICHED NUCLEAR 
FRACTION – Upon PGJ2 treatment (20m, 16h) proteins from 
total lysates from control (C) and treated (T) cells were 
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separated into cytoplasmic (CYTOP.) and enriched nuclear 
fractions as well as into a pellet fraction. The samples 
were then analyzed by western blotting. In PGJ2-treated 
cells tau was detected mostly in the enriched nuclear 
fraction where full length tau (TAU FL) was also apparent 
(FIG. 7A AND B, lane 4). Truncated tau (tau) was detected 
with monoclonal and polyclonal antibodies (FIG. 8) that 
react with different epitopes: Tau C3 (monoclonal, epitope 
a.a. 412-421) from Covance, tau clone 5 (monoclonal, 
epitope a.a. 210-241) courtesy from Dr. Binder, TauY9 
(polyclonal, epitope a.a. 12-27) from BioMol, and pan tau 
clone 13 (monoclonal, epitope a.a. 2-18) from Santa-Cruz. 
these results confirm that the PGJ2-induced tau detected 
in the enriched nuclear fraction is indeed truncated tau.  
As expected, most of PARP is localized to the enriched 
nuclear fraction (Fig. 7C, lanes 3 and 4) and the heat 
shock chaperone HSP90 is predominantly found in the 
cytoplasm (Fig. 7D, lanes 1 and 2), attesting to the 
efficacy of the subcellular fractionation protocol (it is 
predicted that less than 10% contamination between 
enriched nuclear and cytoplasmic fractions is obtained 
with this protocol). However, probing a parallel gel with 
an anti--tubulin antibody demonstrated that this protein, 
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which is a component of the microtubule organizing center 
(MTOC) was distributed to approximately the same extent in 
all subcellular fractions (Fig. 7E, lanes 1-6). This 
finding suggests that tau (FL and tau) detected in the 
enriched nuclear fraction may be associated with the MTOC, 
since this intracellular structure co-localizes with the 
enriched nuclear fraction as well. Interestingly, two -
tubulin bands were immunodetected in the pellet fraction 
(Fig. 7E, lanes 5 and 6). The heavier band may correspond 
to monoubiquitinated -tubulin 159. 
 
2.4.6 PGJ2 INDUCES THE FORMATION OF A LARGE 
PERINUCLEAR TAU AGGREGATE NEXT TO A NUCLEAR 
INDENTATION - The distribution of tau was altered by PGJ2 
treatment. In control cells tau (green) exhibits a uniform 
distribution that extends from the nuclear envelope out to 
the periphery of the cell (Fig. 9A, larger in D). The 
nucleus is stained red with a carbocyanine monomer (TO-
PRO-3 iodide, Invitrogen). Upon treatment with 20M PGJ2 
for 16h tau immunoreactivity (Fig. 9B, larger in C) 
emerged as a large perinuclear aggregate (white arrows) 
next to a nuclear indentation. The large perinuclear 
aggregate detected in PGJ2-treated cells resembles 
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aggresomes, first described by Kopito‟s group 160. 
Aggresomes are thought to be deposition sites for proteins 
that escape degradation by the ubiquitin/proteasome 
pathway and to be co-localized with centrosome/MTOC 
markers such as -tubulin [reviewed in 161].  
2.4.7 TAU IS CLEAVED AT ASP421 IN RAT PRIMARY 
CORTICAL NEURONAL CULTURES TREATED WITH PGJ2 - We 
incubated rat E18 primary cortical neuronal cultures with 
20M PGJ2 for 16h. As shown in Fig. 10A (lanes 3 and 5, 
designated C) the TauC3 antibody did not react with any 
major tau bands in control cultures. In cells treated with 
PGJ2 (boxed lanes 4 and 6, designated T) TauC3 
immunoreactivity detected truncated tau (tau) with a 
molecular mass similar to tau identified in human SK-N-SH 
cells treated with PGJ2 (lane 2). The pan tau C5 antibody 
(Fig. 10B) detected full length tau in control cells 
(lanes 7 and 9) and full length as well as tau in PGJ2-
treated cells (boxed lanes 8 and 10). The blots were 
probed with anti-actin as protein loading control (Fig. 
10C). 
 Upon immunofluorescent analysis with the TauC3 antibody, 
dystrophic-like neurites were observed in the cortical 
neuronal cultures treated with PGJ2 (Fig. 10D and E). 
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Sites of neuritic dystrophy are suggested by bulb-like 
accumulations of tau (arrowheads) and punctuate appearance 
(arrows) in the PGJ2-treated neurons. Control cultures did 
not exhibit any immunofluorescence with the TauC3 antibody 
(not shown). This is not surprising, since as shown in 
Fig. 10A (lanes 3 and 5), no immunoreactivity by western 
blot analysis with the same antibody was detected under 
control conditions. 
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2.5. DISCUSSION 
2.5.1 PGJ2 MODULATES TAU CLEAVAGE (ASP421) 
THROUGH CASPASE MEDIATED PROTEOLYSIS - Our study 
provides the first evidence that a product of 
inflammation, PGJ2, modulates tau cleavage at Asp421 
through caspase-mediated proteolysis in neuronal cells. 
This is important in view of the fact that studies from 
other groups indicate that caspase-cleavage of tau at 
Asp421 is an early event in AD tangle pathology 
162;163
. We 
also demonstrate for the first time that PGJ2-induced tau 
cleavage at Asp421 (tau) coincides with the onset of 
apoptosis indicated by caspase activation as well as by 
the concurrence of tau and PARP cleavage. Only caspase 
inhibitors attenuated tau levels induced by PGJ2. Neither 
calpain nor cathepsin inhibitors diminished tau levels. 
Our data also indicate that tau must be cleared by 
lysosomal proteases, since cathepsin inhibition by 
pepstatin or by high concentrations (20M) of caspase 
inhibitors that also affect cathepsins 
164
, caused an 
increase in PGJ2-induced tau levels.  
A similar tau cleavage at Asp421 was observed in rat 
cortical 
165;166
 and hippocampal 
167
 neurons as well as 
organotypic hippocampal slice cultures 
168
 treated with A42 
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( amyloid 1-42), suggesting a link between amyloid and 
NFTs in AD. Other studies demonstrated that prostaglandins 
(PGA1, PGE1, PGE2) increase A levels in neuroblastoma 
cells 
169;170
 and that deletion of the PGE2 receptor EP2 
reduces amyloid burden in an AD transgenic mouse model 
171
. 
It is tempting to speculate that as a result of 
inflammation, prostaglandins increase A levels which in 
turn trigger tau cleavage at Asp421. This cascade of 
events would suggest a proinflammatory pathway linking 
amyloid and tau pathologies in AD. 
2.5.2 PGJ2-INDUCED TAU CLEAVAGE IS PPAR-
INDEPENDENT BUT OXIDATION-DEPENDENT - Our data show 
that PGJ2-induced tau cleavage is PPAR-independent. A 
PPAR activator (ciglitazone) failed to mimic the PGJ2 
effect on tau and a PPAR-antagonist (BADGE) did not 
prevent tau cleavage induced by PGJ2. This is not 
surprising, since PPAR-agonists have been linked to 
neuroprotection rather than neurotoxicity 
172
. In fact PPAR 
agonists are being considered as AD therapeutic agents 
because they modulate inflammatory responses 
173
. However, 
the protective effect of PPAR-agonists seems to be 
mediated by an anti-oxidant effect 
174
. The finding that 
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the anti-oxidant NAC prevents PGJ2-induced tau cleavage as 
well as other PGJ2-dependent toxic effects 
175
, supports 
the view that PGJ2 neurotoxicity is indeed mediated by its 
pro-oxidant nature. 
2.5.3 BUILD-UP OF UBIQUITINATED PROTEINS 
PRECEDES CASPASE ACTIVATION AND TAU FORMATION - AD 
and many other neurodegenerative disorders, such as 
Parkinson‟s disease and amyotrophic lateral sclerosis, 
share an intriguing morphological feature that is the 
intracellular deposition of aggregated and ubiquitinated 
proteins in neurons of the affected CNS areas [reviewed in 
176
]. The relationship between the accumulation of 
ubiquitinated proteins, which is a general phenomenon in 
these disorders, and more disease-specific pathology such 
as NFT in AD remains to be elucidated.  
Our studies clearly demonstrate that the abnormal build-
up of ubiquitinated proteins is an early event in the 
cytotoxic response to PGJ2. The accumulation of 
ubiquitinated proteins observed upon treatment with 
prostaglandins of the J2 series is a result of their 
inhibitory effect both on deubiquitination 
177-179
 and 
proteasome activity 
180-182
. On the other hand, the reaction 
between cysteine thiol groups in proteins and the J2 
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prostaglandins through Michael addition provokes changes 
in protein tertiary structure 
183
 that could impede protein 
degradation and lead to their accumulation. Overall, the 
chemical properties of J2 prostaglandins and their pro-
oxidant and UPP disrupting effects render them extremely 
capable of bringing about the build-up of pro-apoptotic 
and detrimental proteins, such as p53 and ubiquitinated 
proteins 
184
. 
Our finding that the build-up of ubiquitinated proteins 
upon PGJ2-treatment precedes the onset of apoptosis 
suggests that cells launch the pro-death pathway if they 
do not succeed in removing the overwhelming levels of 
ubiquitinated proteins. Once apoptosis is activated 
caspase-mediated proteolysis is responsible for inducing 
partial protein cleavage, leading to the generation of, 
for example, truncated tau. Caspase-mediated proteolysis 
seems to be a more general phenomenon that cleaves not 
only PARP and tau but many other substrates recently 
identified by a proteome-wide effort to establish the 
caspase substrate repertoire 
185
.  Full-length tau is a 
highly soluble protein, yet in AD it appears as abnormal 
aggregates. Previous studies propose that truncated tau 
induces the aggregation of full-length tau and that tau 
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aggregates are toxic to cells 
186-188
. Therefore, tau may 
serve as a seed for cytotoxic protein aggregation.  
2.5.4 PERINUCLEAR TAU AGGREGATES AND DYSTROPHIC 
NEURITES - We found that tau is detected in an enriched 
nuclear fraction of PGJ2-treated SK-N-SH cells. It is 
clear that the enriched nuclear fraction also contains -
tubulin. The latter is a protein found in the cytoplasm 
but is concentrated at the microtubule organizing center 
(MTOC/centrosome) where it regulates microtubule 
nucleation. MTOCs are located near the nucleus, therefore 
it is not surprising that they co-fractionate in the 
enriched nuclear fraction. In our previous studies we 
demonstrated that PGJ2 induces the collapse of the 
cytoskeleton/ER 
189
. The PGJ2-dependent cytoskeletal 
rearrangement paralleled the development of a large MTOC 
aggregate co-localized with -tubulin and also containing 
ubiquitinated proteins. We now demonstrate that this 
perinuclear aggregate that resembles an aggresome 
190
 is 
also enriched in tau. These data suggest that tau is 
driven to the perinuclear aggregate by the microtubule 
collapse. We also established that PGJ2 caused neurite 
dystrophy in rat E18 primary cortical neurons indicating 
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that neuritic pathology is not always linked to amyloid 
plaques. 
Notably, upon subcellular fractionation, we detected two 
-tubulin forms (~52kDa and 60kDa) in the pellet fraction 
of SK-N-SH cells. In addition, upon PGJ2-treatment, the 
52kDa form became the predominant one. These two -tubulin 
forms differ in molecular mass by ~8kDa, suggesting that 
the ~60kDa form corresponds to monoubiquitinated -tubulin. 
Monoubiquitination of -tubulin at K48 by the ubiquitin 
ligase BRCA1 was shown to regulate centrosome numbers in 
breast cancer cells 
191
. BRCA1 was recently postulated to 
modulate neuronal cell cycle re-entry in AD 
192
. 
Furthermore, reexpression of cell cycle proteins and DNA 
synthesis in mice expressing non-mutant human tau support 
the hypothesis that tau pathology is linked to 
neurodegeneration via abnormal incomplete cell-cycle 
reentry 
193
. Cell cycle suppression in neurons seems to be 
crucial to neuron survival 
194
. These studies together with 
our observation that PGJ2 treatment potentially attenuates 
-tubulin monoubiquitination, may indicate a possible link 
between BRAC1 and its -tubulin substrate with cell cycle 
reentry in AD neurodegeneration. 
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In conclusion, it is clear that PGJ2 is not the only 
cytotoxic agent produced by activated glia (microglia and 
astrocytes) as a result of the chronic inflammatory 
process. Other factors, such as nitric oxide, IL1, IL6, 
TNF and reactive oxygen species (e.g. superoxide anion) 
are also produced under conditions of inflammation. All of 
these cytotoxic agents must work in concert to induce 
synergistic neurotoxicity leading to neurodegeneration 
195;196
. Based on the data obtained with PGJ2 we propose a 
model in which any stimulus (physical, chemical or 
infectious) capable of inducing inflammation in a 
particular brain area, activates microglia and astrocytes. 
The activated glia release toxic products (such as PGJ2) 
onto neighboring neurons that cause UPP impairment or 
overwhelm proteasome activity causing the accumulation of 
ubiquitinated proteins. If these Ub-proteins fail to be 
cleared, apoptosis is triggered. During apoptosis caspase-
mediated proteolysis generates aggregation prone partial 
protein digests such as tau. These cleavage products of 
caspase-mediated proteolysis may serve as seeds for 
cytotoxic protein aggregation. Protein aggregation in 
conjunction with caspase activation would thus promote 
neurodegeneration. This sequence of events could explain 
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many pathological features of the AD neurodegenerative 
process.  
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3.1. ABSTRACT 
 Accumulation of ubiquitinated proteins in inclusions is 
common to various neurodegenerative disorders, such as 
Parkinson‟s disease, Alzheimer‟s disease and amyotrophic 
lateral sclerosis, although it occurs in selective neurons 
in each disease. The mechanisms generating such abnormal 
aggregates and their role in neurodegeneration remain 
unclear. Inclusions appear in familial and non-familial 
cases of neurodegenerative disorders suggesting that 
factors other than particular mutations contribute to 
protein accumulation and aggregation. 
 Proteasome impairment triggered by aging or conditions 
such as oxidative stress, may contribute to protein 
accumulation and aggregation in neurodegeneration. To test 
this hypothesis in mouse neuronal cells, we over-expressed 
a 20S proteasome 5 subunit with an active site mutation. 
The N-terminal threonine to alanine substitution resulted 
in impairment of the chymotrypsin-like activity, which is 
a rate-limiting step in protein degradation by the 
proteasome. The Thr1Ala mutation was not lethal under 
homeostatic conditions. However, this single amino acid 
substitution significantly hypersensitized the cells to 
oxidative stress triggering not only the accumulation and 
aggregation of ubiquitinated proteins including synuclein, 
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but also cell death. Our results demonstrate that this 
genetic manipulation of proteasome activity involving a 
single amino acid substitution causes the formation of 
protein aggregates in stressed neuronal cells 
independently of the occurrence of mutations in other 
cellular proteins.  These results support the notion that 
proteasome disruption may be central to the development of 
familial as well as sporadic cases of neurodegeneration. 
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3.2. INTRODUCTION 
 In a wide variety of neurodegenerative disorders, such 
as AD, Parkinson‟s diseases (PD) and amyotrophic lateral 
sclerosis (ALS), aggregates of ubiquitinated proteins are 
detected in neuronal inclusions indicating that the 
ubiquitin/proteasome pathway may be deficient [reviewed in 
197
]. The relationship between the formation of the 
intracellular inclusions and the selective neuronal cell 
death that occurs in the various neurodegenerative 
disorders remains undefined.  
 The ubiquitin/proteasome pathway is responsible for the 
turnover of many regulatory and misfolded proteins and is 
essential for cell growth as well as cell viability 
198
. 
Proteolysis of polyubiquitinated proteins in this pathway 
is carried out by the 26S proteasome 
199
, which includes a 
regulatory component, the 19S particle, and a proteolytic 
component, the 20S proteasome 
200
. The latter is composed 
of 28 subunits arranged in four heptameric-stacked rings 
201
 and has a broad specificity hydrolyzing peptide bonds 
on the carboxyl side of hydrophobic (chymotrypsin-like), 
basic (trypsin-like) and acidic (caspase-like) amino acids 
202
.  
 Under homeostatic conditions, polyubiquitinated proteins 
do not accumulate in cells since they undergo selective 
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proteolysis by the ubiquitin/proteasome pathway. The 
neuronal inability to eliminate polyubiquitinated proteins 
may result from a malfunction or overload of the 
ubiquitin/proteasome pathway or from structural changes in 
the protein substrates halting their degradation [reviewed 
in 
203
]. 
Our studies investigate the possibility that impairment 
of proteasome activity may be an important contributor to 
neurodegeneration. We previously established that 
incubations of mouse neuronal HT4 cells with proteasome 
inhibitors led to an accumulation of ubiquitinated 
proteins and to a decrease in cell viability 
204
. However, 
proteasome inhibitors may exert nonspecific effects as 
bound molecules or through interactions with other 
cellular proteins. To overcome this difficulty we decided 
to genetically manipulate proteasome activity.  
In the present study, disruption of proteasome activity 
was achieved by generating a mutation on the active site 
of its constitutive 5 catalytic subunit. The latter 
accounts for the chymotrypsin-like activity, which 
carries-out the rate-limiting step in protein degradation 
by the proteasome 
205
. The N-terminal Thr of 5 was mutated 
to Ala because the 20S proteasome is a threonine protease 
in which the nucleophilic attack is mediated by the N-
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terminal Thr of processed, catalytically active  subunits 
206
.  
 The results from our studies clearly demonstrate that in 
mouse neuronal HT4 cells, expression of a 20S proteasome 5 
subunit mutant (T1A) that impairs its chymotrypsin-like 
activity, is not dominant lethal under homeostatic 
conditions. However, this single amino acid substitution 
causes accumulation of ubiquitinated proteins in 
aggregates and cell death in stressed mammalian cells, 
under conditions in which stable transfectants expressing 
the WT5 construct or vector control are not affected. 
These findings underscore the requirement for an optimally 
functional proteasome for protein turnover under stress 
conditions and support the view that proteasome impairment 
may be a key player in sporadic cases of neurodegenerative 
disorders.  
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3.3. MATERIALS AND METHODS 
(only those performed by Lisette T. ARNAUD) 
 3.3.1 GLYCEROL DENSITY GRADIENT CENTRIFUGATION  
 Cells were lysed in 0.01M Tris-EDTA, pH 7.5 by 
sonication and the lysates were centrifuged for 10-min at 
19,000g at 4
o
C. The cleared supernatants were subjected to 
centrifugation at 83,000Xg for 24h in a Beckman SW41 rotor 
in a 10-40% glycerol gradient made in the same lysis 
buffer. Following centrifugation 14 fractions (500l each) 
were collected and analyzed. 
 3.3.2 PEPTIDASE ACTIVITIES  
 Peptidase activities were assayed colorimetrically after 
24h incubations at 37
o
C as described in 
207
. The 
chymotrypsin-like activity was measured with the 
substrates Suc-LLVY-AMC and Z-GGL-pNA and the caspase-like 
activity with Z-LLE-NA.  All substrates were purchased 
from Bachem Bioscience Inc. 
 3.3.3 IMMUNOCYTOCHEMISTRY  
 For immunofluorescence, cells were fixed in ice cold 
methanol:acetone (1:1) at –20oC and co-incubated with anti-
ub-conjugates (1:250) and anti-synuclein (1:100) 
antibodies. The secondary antibodies (1:50) were Texas 
red-labeled donkey anti-rabbit and fluorescein-labeled 
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donkey anti-goat (Jackson laboratories, Inc.).  Slides 
were mounted with vectashield medium containing DAPI 
(Vector). Cell staining was always visualized with an 
Optiphot-2 fluorescence microscope (Nikon). 
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3.4. RESULTS 
(only those performed by Lisette T. ARNAUD) 
 3.4.1 THE CHYMOTRYPSIN-LIKE ACTIVITY OF 
PROTEASOMES IS SIGNIFICANTLY REDUCED IN MUTA5 
STABLE TRANSFECTANTS TREATED WITH CADMIUM -  To 
verify whether the hypersensitivity of the Muta5 stable 
transfectants correlated with a decrease in proteasome 
chymotrypsin-like activity, cells were incubated for 24h 
with a concentration of Cd
2+
 (9M) at which only Muta5 
stable transfectants show an increase in the levels of 
ubiquitinated proteins and a loss in cell viability. Equal 
amounts of cell lysates (1mg protein/sample) from WT5 and 
Muta5 stable transfectants were then fractionated by 
glycerol density gradient centrifugation. Each fraction 
was assayed for chymotrypsin-like activity with two 
proteasome substrates (Z-GGL-pNA and Suc-LLVY-AMC) and for 
caspase-like activity with Z-LLE-NA. Values were 
normalized to maximal activity observed in WT5 and Muta5 
stable transfectants. As shown in Fig. 11 (upper panels), 
in wild type and mutant stable transfectants incubated 
without Cd
2+
 (open squares, solid lines), active enzyme 
with chymotrypsin-like activity sedimented with two 
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sedimentation coefficients corresponding to 26S and 20S 
proteasomes, respectively. No differences in chymotrypsin-
like activity were detected in WT5 and Muta5 stable 
transfectants in the absence of cadmium. These results are 
in agreement with those obtained with crude cell extracts, 
since they also correspond to the combined chymotrypsin-
like activity of proteasome particles containing 
endogenous as well as c-myc-tagged 5 subunits. 
 Only slight alterations in the peptidase activity 
profiles were observed in WT5 stable transfectants 
incubated for 24h with 9M Cd2+ (closed squares, broken 
lines). However, the chymotrypsin-like activity of the 
Cd
2+
-treated Muta5 stable transfectants was noticeably 
reduced (closed squares, broken lines), particularly in 
the fractions corresponding to the 26S proteasome elution 
position (Fig. 11, hatched area). These findings correlate 
well with the accumulation of ubiquitinated proteins 
observed only in the Cd
2+
-treated Muta5 stable 
transfectants. The caspase-like activity of the proteasome 
was also perturbed in the Cd
2+
-treated Muta5 stable 
transfectants (Fig. 11). These results indicate that Cd
2+
 
may increase the structural instability of 26S proteasome 
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particles harboring the Muta5/c-myc subunit when they are 
subjected to glycerol gradient centrifugation. 
 Western blot analyses of the glycerol gradient 
centrifugation fractions (Fig. 11, lower panels) 
demonstrate that the mature forms of WT5/c-myc (24kDa, 
arrows #1) and Muta5/c-myc (26kDa, arrows #3) are present 
in the fractions in which proteasome activity can be 
measured, attesting to their incorporation into the 
proteasome. Notably, the levels of mature Muta5/c-myc 
detected in Fig. 11 are significantly lower than those of 
mature WT5/c-myc. 
 3.4.2 MUTA5 STABLE TRANSFECTANTS TREATED WITH 
CADMIUM DEVELOP LARGE UBIQUITIN CONJUGATE 
AGGREGATES CONTAINING SYNUCLEIN - Ub-conjugates 
accumulate in cytosolic inclusions, such as Lewy bodies 
present in the substantia nigra of brains from Parkinson's 
disease patients. These inclusions also contain synuclein, 
which was shown to be degraded by the proteasome 
208
. For 
these reasons, we investigated the distribution of Ub-
conjugates and synuclein in the mouse HT4 cells. The Cd
2+
-
treated Muta5 stable transfectants exhibited large Ub-
protein aggregates detected with the same anti-Ub antibody 
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employed in the Western blot analysis. Immunofluorescence 
studies revealed that synuclein was co-localized with most 
of the Ub-protein aggregates detected in the Cd
2+
-treated 
Muta5 stable transfectants (Fig. 12a‟-d‟). Most of vector 
and WT5 stable transfectants treated with Cd2+ exhibited 
only minor Ub-protein aggregates, although large 
aggregates could also be detected in a few of these cells. 
Furthermore, in Cd
2+
-treated WT5 stable transfectants, 
synuclein appeared to be evenly distributed throughout the 
cell excluding the nucleus (Fig. 12a-d). No Ub-protein 
aggregates could be found in untreated cells. These 
results strongly support a role for proteasome impairment 
in inclusion formation.   
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3.5. DISCUSSION 
Impairment of the ubiquitin/proteasome pathway is 
implicated in a variety of neurodegenerative disorders, 
such as Parkinson‟s disease [reviewed in 209]. Proteasome 
dysfunction triggered by harmful conditions such as 
oxidative stress [reviewed in 
210
] or aging [reviewed in 
211
] is likely to decrease the degradation rate of 
ubiquitinated proteins causing their aggregation and 
accumulation in inclusions. Whether proteasome impairment 
or the accumulation of ubiquitinated proteins are a cause 
or consequence of the neurodegenerative process has not 
been clearly demonstrated.  
Most studies addressing the outcome of proteasome 
inhibition on neuronal cells, such as those in 
212
, draw on 
a pharmacological approach with synthetic proteasome 
inhibitors. We decided to take advantage of a genetic 
manipulation of proteasome function because, although it 
is not a replacement for pharmacology, it offers a greater 
degree of specificity. We generated stable transfected 
mouse neuronal HT4 cells expressing a mutant 5 subunit of 
the 20S proteasome that differs from the wild type 5 sub-
unit by only one amino acid in the active site.  
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 This strategy enabled the generation of stable 
transfectants in which the chymotrypsin-like activity was 
impaired but not completely abolished. While there was no 
difference in the survival rate of WT5 and Muta5 stable 
transfectants under homeostatic conditions, the latter 
were hypersensitive to cadmium.  
 A reduction in the chymotrypsin-like activity of 20S 
proteasomes harboring Muta5/c-myc subunits was detected. 
Furthermore, aggregates of ubiquitinated proteins forming 
large inclusions were only detected in the Muta5 stable 
transfectants. Remarkably, the only disparity between 
Muta5 and WT5 stable transfectants is the single T1A 
mutation in the 5 subunit of the 20S proteasome. The 
increase in Cd
2+
-sensitivity conferred by a single amino 
acid substitution in the 5 subunit reinforces the notion 
that a proteasome deficiency unequivocally potentiates the 
harmful effects of oxidative stress as suggested by other 
investigators 
213
,
214
. These studies underscore a synergy 
that may exist between proteasome deficiency and cellular 
stress in triggering neurodegeneration. Cells must 
constantly rely on the proteasome to remove mutant 
proteins or abnormal proteins produced under stress 
conditions. Impairment of proteasome function would thus 
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exacerbate the deleterious effects of stress conditions, 
most likely jeopardizing the recovery process. In 
conclusion, disruption of proteasome activity could thus 
be central to the development of familial as well as 
sporadic cases of neurodegeneration. 
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4.1. ABSTRACT 
 Aging is associated with loss of quality control in 
protein turnover. The ubiquitin-proteasome pathway is 
critical to this quality control as it degrades mutated 
and damaged proteins. We identified a unique aging-
dependent mechanism that contributes to proteasome 
dysfunction in Drosophila melanogaster. Our studies are 
the first to show that the major proteasome form in old 
(43-47 days old) flies is the weakly active 20S core 
particle while in younger (1-32 days old) flies highly 
active 26S proteasomes are preponderant. In conclusion, 
our data reveal a previously unknown mechanism that 
perturbs proteasome activity in “old-age” female and male 
Drosophila most likely depriving them of the ability to 
effectively cope with proteotoxic damages caused by 
environmental and/or genetic factors. 
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4.2. INTRODUCTION 
 A fundamental characteristic of aging 215 and age-related 
neurodegenerative disorders 
216;217
 is the accumulation and 
aggregation of ubiquitinated proteins in abnormal neuronal 
inclusions, such as neurofibrillary tangles in Alzheimer‟s 
disease and Lewy bodies in Parkinson‟s disease. The 
mechanisms causing the aggregation of ubiquitinated 
proteins and its role in aging and age-related 
neurodegeneration remain elusive. A decline in proteasome 
activity with the aging process has been shown in a 
variety of mammalian organs and tissues [reviewed in 
218
]. 
The loss of proteasome activity with aging has been 
associated with decreased subunit expression, alterations 
and/or replacement of proteasome subunits and formation of 
inhibitory cross-linked proteins [reviewed in 
219;220
]. Food 
restriction, which is currently the only experimental 
paradigm that halts the aging process, prevents the age-
dependent changes in proteasome function and structure in 
mice and rats, further supporting the notion that the 
proteasome plays a role in the aging process [reviewed in 
221
]. Proteasome dysfunction thus provides a link between 
environmental and genetic factors associated with aging 
and aging-related neurodegeneration.  
 Herein, we demonstrate a significant decline in 
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proteasome activity in female and male old (43-47 days of 
age) flies compared to younger (1 to 32 days of age) 
flies. Notably, we found that the major proteasome form in 
old flies is the 20S core particle, while in younger flies 
the 26S holoenzyme is the preponderant proteasome form. 
These findings establish that autoinhibited 20S 
proteasomes prevail in old flies whereas the fully-
assembled 26S proteasome is highly active in young flies. 
Our results support the view that an aging-dependent 
disassembly of the 26S proteasome is an important risk 
factor in aging. 
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4.3. MATERIALS AND METHODS 
(only those performed by Lisette T. ARNAUD) 
 4.3.1 IN-GEL PROTEASOME ACTIVITY AND DETECTION 
Mixed populations of females and males for each age 
group were analyzed. Flies were harvested with buffer A 
[50mM Tris-HCl, pH 7.4, 5mM MgCl2, 5mM ATP (grade 1; Sigma, 
St. Louis, MO), 1mM DTT and 10% glycerol], which preserves 
26S proteasome assembly 
222
. Following homogenization on 
ice with a teflon pestle for microcentrifuge tubes (100 up 
and down strokes), sonication on ice (2X10s with a 5s 
interval) and centrifugation (19,000xg, 15-min at 4
o
C) the 
protein content of the cleared supernatants was determined 
with the Bradford assay (BIO RAD). The cleared 
supernatants were resolved by non-denaturing PAGE using a 
modification of the method described in 
223
. 
We used a three step gradient gel with approximately 
similar amounts of 5%, 4% and 3% polyacrylamide containing 
Rhinohide
TM
 polyacrylamide strengthener (Invitrogen-
Molecular Probes, Carlsbad, CA). Bromophenol blue was 
added to the samples prior to loading. Non-denaturing 
minigels were run at 125Volts for 3 hours.  
For detection of proteasome activity, the gels were 
incubated on a rocker for 10 to 30-min (depending on 
  
 
84 
protein amount loaded) at 37
o
C with 15ml of 0.4mM Suc-LLVY-
AMC in buffer B (buffer A modified to contain 1mM ATP). 
Proteasome bands were visualized upon exposure to UV light 
(360nm) and were photographed with a NIKON Cool Pix 8700 
camera with a 3-4219 fluorescent green filter (Peca 
Products, Inc.). Semi-quantitative analysis of the bands 
corresponding to proteasome activity was performed by 
image analysis with the ImageJ program (Rasband, W.S., 
ImageJ, U. S. National Institutes of Health, Bethesda, 
Maryland, USA, http://rsb.info.nih.gov/ij/, 1997-2006). 
Proteins on the native gels were then transferred 
(110mA) for 2.5h onto PVDF membranes. Western blot 
analysis was carried-out for detection of the 26S and 20S 
proteasomes with our anti-d5 affinity purified antibody 
(1:4000, Bio-Synthesis, TX). The peptide NH2-
(GC)DSGYHWDLEDKEAQE-COOH was used to produce the anti-d5-
specific antibody and corresponds to amino acids 213-227 
of the Drosophila d5 subunit. The anti-d5 antibody reacts 
with a core particle subunit (d5) thus detecting both the 
26S and 20S proteasomes. Upon incubation with the 
secondary antibody, antigens were visualized by a 
chemiluminescent horseradish peroxidase standard method 
with the ECL reagent.  
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To determine the total protein pattern of young and old 
flies, parallel native gels were stained with Coomassie 
blue after assessment of proteasome activity with Suc-
LLVY-AMC.  
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4.4. RESULTS 
(only those performed by Lisette T. ARNAUD) 
 4.4.1 26S PROTEASOME ASSEMBLY AND ACTIVITY ARE 
IMPAIRED IN OLD (43-47 DAYS) FLIES - We postulated 
that the decline in proteasome activity observed in old 
flies could be due to impaired proteasome assembly. To 
test this premise we compared proteasome activity in flies 
of different age groups. Proteasome activity in cleared 
supernatants was assessed by an in-gel assay as described 
under “methods”. No proteasome activity could be detected 
in the residual pellet fraction (not shown). As a marker, 
an aliquot of partially purified 20S proteasomes from 
Srabbit reticulocyte lysates (20S) was run in a parallel 
lane.  
 Proteasome levels and activity (Fig. 13) from mixed 
populations of females and males were compared between two 
age groups: young (1-2 days) and old (43-47 days). In 
young flies, most of the proteasome activity assessed with 
the short substrate Suc-LLVY-AMC coincided with the 26S 
holoenzyme (not the 20S) form of the proteasome (Fig. 13, 
left panel). The in-gel chymotrypsin-like activity assay 
revealed that the proteasome activity in young flies (Y) 
coincided almost exclusively with the 26S holoenzyme, in 
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its symmetrical (two capped) and asymmetrical (one capped) 
forms. Only extremely low levels of chymotrypsin-like 
activity were associated with the 20S proteasome, 
demonstrating that the 26S holoenzyme is the most active 
in vivo form of the proteasome in young flies. In 
contrast, the chymotrypsin-like activity of both the 26S 
and the 20S proteasomes was low in old flies (O).  
 Immunoblot analysis of the native gels with our anti-d5 
antibody revealed that, in young flies, proteasomes were 
detected as the 26S holoenzyme in its symmetric (two caps) 
and asymmetric (one cap) forms as well as the 20S 
proteasome (Fig. 13, middle panel). In contrast, in old 
flies, proteasomes were found almost exclusively as 20S 
particles (Fig. 13, middle panel). These finding establish 
that low-activity 20S proteasomes prevail in old flies 
while the assembled 26S holoenzyme is highly active in 
young flies.  
Following assessment of proteasome activity with Suc-
LLVY-AMC, native gels were stained with Coomassie blue 
(Fig. 13, right panel). The total protein pattern of young 
and old flies was slightly but consistently different. 
This difference was not caused by post-harvesting protein 
degradation as similar patterns were observed when flies 
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were harvested with or without a protease inhibitor 
cocktail (not shown). 
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4.5. DISCUSSION 
In this paper we show for the first time that the aging 
process is associated with the disassembly of the 26S 
proteasome with a clear loss of its activity. The decline 
in 26S holoenzyme levels in old flies (43-47 days of age) 
coincides with increased levels of the 20S proteasome. 
Clearly, the activity of the 20S proteasome failed to 
decline. However, our studies demonstrate that the free 
20S core particle is nearly inactive in all flies 
independently of their age group. Accordingly, the 
majority of the proteasome chymotrypsin-like activity 
coincides with the 26S proteasome, the levels of which 
decline sharply in 43-47 days old female and male flies. 
That the 20S proteasome is almost inactive is not 
particular to flies, as a similar phenomenon was observed 
in yeast 
224
. It is well established that in the outer 
rings of the 20S core particle, the conformation of the  
subunits is such that it seals the entrance into the 
catalytic chamber 
225
. Activation of the 20S proteasome 
thus requires disruption of the inflexible and passive 
barrier provided by the outer  rings. The opening of 
these gates to the catalytic chamber is triggered by 
regulatory complexes, such as the 19S and the 11S 
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regulatory particles [reviewed in 
226
]. In vitro studies 
with purified 20S proteasomes demonstrated that the 
closed-gate conformation is also destabilized by the 
binding of some hydrophobic peptides to non-catalytic 
sites on the core particle 
227
 or by certain proteins, such 
as p21 and -synuclein 228. The latter mechanism for 
activation of the 20S core particle has not yet been 
demonstrated to occur in vivo. However, it was proposed 
that because proteasomes diffuse rapidly in the cytoplasm 
and nucleus of mammalian cells, they may continuously 
collide with some of their substrates 
229
. 
Our finding that the disassembly of the 26S proteasome 
is an “old-age” event could explain the presence of 
protein deposits containing ubiquitinated proteins and 
oxidatively modified proteins in non-pathologic aging 
230
 
as well as in a variety of aging-related neurodegenerative 
disorders including Alzheimer‟s and Parkinson‟s diseases 
and amyotrophic lateral sclerosis, to name a few 
231
. The 
reduction in assembled 26S proteasomes not only will 
affect normal protein turnover but also most likely 
deprives old flies of the ability to effectively cope with 
proteotoxic damages caused by life long environmental 
and/or genetic factors. 
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CHAPTER V 
 
 
 
 
MODEL AND CONCLUSIONS  
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Neurodegenerative diseases such as AD and PD are age 
related diseases, and determining the sequence of events 
that might span over an entire life is today‟s challenge. 
In the case of AD, even though studies, models and 
hypotheses have flourished over the last two decades 
little is known about the beginning of the pathology and 
when symptoms are detected the neurodegeneration is so 
advanced that little can be done. There are however 
ubiquitous components to these neurodegenerative 
disorders: early neuroinflammation and ubiquitinated 
protein aggregates. 
Our hypothesis is that inflammation more than just 
being a side effect of the neurodegenerative pathology is 
an important contributor to the progression of the 
disease. Indeed, we investigated the role of one 
neurotoxic product of inflammation (PGJ2) and demonstrated 
for the first time, that this CNS prostaglandin was able 
to modulate tau cleavage at Asp421 through caspase-
mediated proteolysis in neuronal cells. This discovery is 
very important since for tau to seed PHF formation it must 
be cleaved first in order for its conformation to change. 
PHFs lead to NFT formation the levels of which correlate 
with cognitive impairment in AD. We linked two known 
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hallmarks of AD, neuroinflammation and tau cleavage, 
suggesting how a physiological event i.e. inflammation, 
can lead to pathological features through caspase-mediated 
proteolysis and cell death through apoptosis. Furthermore, 
we demonstrate that upon PGJ2-treatment tau accumulates in 
perinuclear aggregates in SK-N-SH cells or in bulb-like 
structures along dystrophic-like neuritis in rat primary 
cortical neurons. These observations confirm cytoskeleton 
collapse and tau aggregation. 
In AD, tau is a component of NFTs which also contain 
ubiquitinated proteins. The latter are normally target for 
degradation by the proteasome. Other neurodegenerative 
diseases besides AD are also characterized by ubiquitin-
protein aggregates. The formation of these aggregates 
suggests that the activity of the proteasome is perturbed. 
In this study we demonstrate that proteasome impairment 
due to a mutation in the subunit that carries-out the 
chymotrypsin-like, increases the vulnerability of cells to 
stress conditions and causes the formation of ubiquitin-
protein aggregates. These findings support the notion that 
proteasome impairment is indeed associated with the 
formation of ubiquitin-protein aggregates. The sequence of 
events suggested by our results (see scheme below) starts 
with the triggering of inflammatory events by a variety of 
  
 
94 
external stimuli. The resulting gliosis and pro-
inflammatory factors (such as PGJ2) released in the 
proximity of the neurons affect a diversity of cellular 
functions with dramatic consequences. Indeed the 
impairment of the UPP pathway prevents removal of 
misfolded proteins generated by inflammation-induced 
oxidative stress, leading to accumulation of ubiquitinated 
proteins. As the ubiquitinated proteins accumulate they 
overwhelm the proteasome the activity of which is affected 
by the inflammatory factors. Proteasome impairment in 
concert with the accumulation of ubiquitinated proteins in 
the cell trigger apoptosis and caspase-mediated 
proteolysis. Caspases will then cleave the microtubule 
binding protein Tau generating an insoluble fragment prone 
to aggregation thus promoting formation of protein 
aggregates. In addition, caspases cleave other 
cytoskeletal proteins, such as tubulin and actin, 
resulting in the complete collapse of the cell scaffold. 
All of these events accelerate the deadly fate of the cell 
leading to neurodegeneration.  
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It is not clear why AD and other neurodegenerative 
disorders associated with the build-up of ubiquitinated 
proteins, such as in PD and ALS, are associated with 
aging. We demonstrate in Drosophila that aging is 
associated with a decrease in proteasome activity, 
supporting a role for the aging-dependent proteasome 
impairment in protein aggregation observed in these 
diseases. We established that in Drosophila the 26S fully 
assembled proteasome was preponderant in “young” flies 
while the 20S core particle, which is catalytically 
inactive, prevailed in “old” flies.  These results provide 
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a basis for understanding how proteasome function is 
affected by aging.  
Overall our hypothesis (scheme next page) is that, 
during the lifespan of an individual, the CNS is 
frequently subjected to proteotoxic damages caused by 
environmental and/or genetic factors, some of which may 
induce neuroinflammation. Toxic products of inflammation 
can further exacerbate the generation of abnormal and 
misfolded proteins that would normally get ubiquitinated 
and processed by the proteasome (1). However as the 
individual ages, the well oiled machinery gets gripped. 
The proteasome disintegrates and so it fails to remove the 
ubiquitinated proteins (2). These ubiquitinated proteins 
tend to aggregate within the cells disrupting its 
metabolism and launching a death pathway, such as 
apoptosis, that could further fuel neuroinflammation (3). 
Activation of apoptosis also initiates the caspase cascade 
leading to cleavage (among other proteins) of tau (4) and 
culminating in massive neurodegeneration. 
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CHAPTER VI 
 
 
FUTURE DIRECTIONS 
  
  
 
99 
The studies described in this thesis revealed that: 
1) Products of inflammation, such as PGJ2, induce tau 
pathology manifested by tau cleavage which coincides with 
apoptosis in human neuroblastoma SK-N-SH cells. These 
results suggest that chronic inflammation could be 
critical to tau pathology in the brain. To confirm this 
hypothesis it would be interesting to test conditioned 
media from LPS-activated microglia on our SK-N-SH cell 
model. We would establish if neuroinflammation factors 
released by microglia, which are usually detected 
surrounding neurons in AD, can induce the same tau 
cleavage as PGJ2. We would also like to study if neuronal 
cells subjected to stress conditions that lead to tau 
cleavage, would attempt to compensate for the loss of tau 
by increasing its expression. 
2) PGJ2 induces the formation of a large perinuclear tau 
aggregate next to a nuclear indentation. Upon PGJ2-
treatment of SK-N-SH cells we detected a large perinuclear 
aggregate detected with a pan tau antibody. However, we 
did not define if the aggregates contain cleaved and/or 
full length tau. It would be of interest to further 
investigate the components of the aggregates to determine 
which tau forms (full length or cleaved) are present as 
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well as if tau is ubiquitinated and/or hyperphosphorylated 
in the same manner as in NFTs.  
We would also like to address the potential toxic role 
of the aggregates, which remains a controversial issue. It 
is thought that aggregated proteins are “neutralized toxic 
proteins”. When cells fail to proteolyse proteins that 
could become toxic if remaining soluble in the cytoplasm, 
it was hypothesized that the aggregation of those “stable” 
proteins is a survival mechanism to segregate them from 
the rest of the cell. We could attempt to prevent tau 
aggregation with, for example, N744 tosylate, known to 
prevent tau aggregation in vitro 
232
. By treating cells 
with PGJ2 alone or in combination with N744, we would 
establish if attenuating protein aggregation would prevent 
cell death. 
The studies proposed in the “future directions” should 
provide valuable information on the involvement of 
inflammation in tau pathology and on the mechanisms that 
drive neurodegenerative disorders, such as AD, that are 
associated with inflammation and protein aggregation. 
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CHAPTER VII 
 
 
FIGURES 
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Figure 1 (next page) – PGJ2 induces accumulation of 
ubiquitinated proteins, tau cleavage and apoptosis in a 
dose-dependent manner.  
(A) and (E) - Western blot analyses to detect tau in total 
extracts of human SK-N-SH neuroblastoma cells (30µg of 
protein/lane) treated with PGJ2 for 16h. In (A) the blot 
was probed with the TauC3 antibody (tau cleaved at Asp421, 
epitope a.a. 412-421). After stripping (A) the blot was 
reprobed with the pan tau (clone 13, epitope a.a. 2-18) 
antibody (E) which reacts with all tau isoforms. Equal 
protein loading was demonstrated by probing the 
immunoblots with the anti-actin antibody (D). (B) Blots 
were stripped and reprobed with the anti-PARP antibody, 
which detects cleaved PARP, an apoptosis marker. (C) Blots 
were stripped and reprobed again with the anti-
ubiquitinated (Ub) proteins antibody. (F) Cell viability 
was assessed with the MTT assay. Data represent the 
mean ± SEM from at least three determinations. The 
viability for each condition was compared to the viability 
of cells treated with vehicle only (control, 100%). The 
asterisk (*) identifies the values that are significantly 
different (p < 0.001) from the control. (G) The levels of 
Ub-proteins (crosses), tau (solid squares) and cleaved 
PARP (open squares) were semi-quantified by densitometry. 
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Data represent the number of pixels (arbitrary units) for 
each PGJ2-concentration as fold-increase over control 
(vehicle only). Molecular mass markers in kDa are shown in 
the middle. Boxes highlight the peaks in tau levels (A) 
and Ub-proteins (C). Similar results were obtained in 
duplicate experiments. TAU, tau cleaved at Asp421; TAU FL 
– full length TAU. 
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Figure 2 (next page)– PGJ2 induces accumulation of 
ubiquitinated proteins, tau cleavage and apoptosis in a 
time-dependent manner. (A) and (E) - Western blot analyses 
to detect tau in total extracts of human SK-N-SH 
neuroblastoma cells (30µg of protein/lane) treated with 
20µM PGJ2 for different times (2h, 4h, 8h, 16h, and 20h). 
In (A) the blot was probed with the TauC3 antibody (tau 
cleaved at Asp421, epitope a.a. 412-421). After stripping 
the blot in (E) was reprobed with the pan tau (clone 13, 
epitope a.a. 2-18) antibody which reacts with all tau 
isoforms. Equal protein loading was demonstrated by 
probing the immunoblots with the anti-actin antibody (D). 
(B) Blots were stripped and reprobed with the anti-PARP 
antibody, which detects cleaved PARP, an apoptosis marker. 
(C) Blots were stripped and reprobed again with the anti-
ubiquitinated (Ub) proteins antibody. (F) Cell viability 
was assessed with the MTT assay. Data represent the 
mean ± SEM from at least three determinations. The 
viability of cells treated with 20µM PGJ2 for each time 
point was compared to the viability of cells treated with 
vehicle only for 24h (control, 100%). The asterisk (*) 
identifies the values that are significantly different 
(p < 0.05) from the control. (G) The levels of Ub-proteins 
(crosses), tau (solid squares) and cleaved PARP (open 
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squares) were semi-quantified by densitometry. Data 
represent the number of pixels (arbitrary units) for each 
time point in cells treated with 20µM PGJ2 as fold-
increase over control (vehicle only). Molecular mass 
markers in kDa are shown in the middle. Boxes highlight 
the peaks in tau levels (A) and Ub-proteins (C). Similar 
results were obtained in duplicate experiments. TAU, tau 
cleaved at Asp421; TAU FL – full length TAU. 
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Figure 3 (next page) – PGJ2 increases caspase activity. 
(A) The activities of caspases 2, 3, 8 and 9 were 
determined in SK-N-SH cells treated with DMSO (vehicle, 
black bars) or treated with 20µM PGJ2 (white bars) for 
16h. Relative caspase activities (RFU = relative 
fluorescent units) normalized for protein (200µg/assay) 
are shown. Results from two determinations are presented 
(mean ± SD). The asterisk (*) identifies the values that 
are significantly different (p≤0.014, T-test) from the 
controls. (B) Caspase 3 activity was determined in SK-N-SH 
cells treated with DMSO (vehicle, 2h and 20h, black bars) 
or treated with 20µM PGJ2 (white bars) for 2h, 4h, 8h, 16h 
and 20h. Relative caspase activities (RFU = relative 
fluorescent units) normalized for protein (200µg/assay) 
are shown. Results from three determinations are presented 
(mean ± SEM). The asterisk (*) identifies the values that 
are significantly different (p < 0.001, ANOVA, Tukey-
Kramer multiple comparison test) from the control. 
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Figure 4 – Individual caspase inhibitors (2µM) attenuate 
the PGJ2-depedent increase in tau levels. Tau levels in 
total extracts of human SK-N-SH neuroblastoma cells (50µg 
of protein/lane) were assessed by Western blot analysis 
with the Tau C3 antibody (tau cleaved at Asp421, epitope 
a.a. 412-421). Cells were treated for 16h with DMSO 
(vehicle, control, lanes 1 and 9) or with 20µM PGJ2 alone 
(lanes 2 and 10, boxed) or with 20µM PGJ2 after a 40-min 
pre-incubation with 2µM of individual caspase inhibitors 
(1 through 6, lanes 3 – 8; 8 through 10, lanes 11-13, and 
13, lane 14) or the pan caspase inhibitor (Z-VAD-FMK, lane 
15). As an FMK negative control, cells were separately 
incubated with Z-FAD-FMK (lane 16). Similar results were 
obtained in duplicate experiments.  
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Figure 5 – Pharmacological manipulation of tau with PPAR 
agonist/antagonist, proteasome or calpain inhibitors and 
the anti-oxidant NAC (next page). Tau levels in total 
extracts of human SK-N-SH neuroblastoma cells (30µg of 
protein/lane) were assessed by Western blot analysis with 
the Tau C3 antibody (tau cleaved at Asp421, epitope a.a. 
412-421). Cells were treated for 16h with DMSO (vehicle, 
control, lanes 1A and 1B) or with 20µM PGJ2 alone (lanes 
2A and 2B, boxed) or with 20µM PGJ2 after a 40-min pre-
incubation with BADGE (lane 3A, PPAR antagonist), pan 
caspase inhibitor (Z-VAD-FMK, lane 4A), or NAC (lane 6B, 
boxed, anti-oxidant). Cells were also separately incubated 
with BADGE (lane 5A), pan caspase inhibitor (lane 6A), 
ciglitazone (PPAR agonist, lane 7A), proteasome inhibitor 
(lanes 4B and 5B), calpain inhibitor (lane 3B), and NAC 
(lane 7B). Similar results were obtained in duplicate 
experiments.  
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Figure 6 – Calpain inhibitors fail to attenuate the PGJ2-
depedent increase in tau levels while cathepsin 
inhibition stabilizes tau (next page). Tau levels in 
total extracts of human SK-N-SH neuroblastoma cells (40µg 
of protein/lane) were assessed by Western blot analysis 
with the Tau C3 antibody (tau cleaved at Asp421, epitope 
a.a. 412-421). Cells were treated for 16h with DMSO 
(vehicle, control, lanes 1A and 9A) or with 15µM PGJ2 
alone (lanes 2 A and 10A) or with 15µM PGJ2 after a 40-min 
pre-incubation with calpain inhibitors (CP1, lane 4A, CP3, 
lane 6A, Z-LL-CHO, lane 8A, and calpeptin, lanes 12A and 
14A). Cells were also treated for 16h with 20µM PGJ2 after 
a 40-min pre-incubation with a cathepsin inhibitor alone 
(pepstatin, lane 2B) or in combination with pan caspase 
inhibitor (lane 3B). Cells were also separately incubated 
with the calpain inhibitors or pepstatin (lanes 3A, 5A, 
7A, 11A, 13A and 1B). Similar results were obtained in 
duplicate experiments.  
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Figure 7 - Subcellular localization of tau. Total lysates 
from SK-N-SH cells treated for 16h with vehicle (C, 
control) or 20µM PGJ2 (T, treated) were fractionated into 
cytoplasmic, enriched nuclear and pellet fractions. 
Western blot analysis was performed to detect levels of 
tau [(A) TauC3 antibody and (B) pan tau antibody], 
cleaved PARP (C), HSP90 (D) and -tubulin (E). Equal 
amounts of protein (40µg) were loaded per lane. Molecular 
mass markers in kDa are shown on the right. Similar 
results were obtained in duplicate experiments.  
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Figure 8 – Detection of PGJ2-induced tau by four 
different antibodies. tau was detected in the enriched 
nuclear fraction (as in fig. 7) of SK-N-SH cells treated 
with DMSO (vehicle, control, C) or PGJ2 (20M, 16h, T) with 
monoclonal and polyclonal antibodies that react with 
different epitopes: Tau C3 (mono) from Covance, tau clone 
5 (mono) courtesy Dr. Binder, Tau Y9 (poly rabbit) from 
BioMol and pan tau clone 13 (mono) from Santa Cruz. tau, 
tau cleaved at Asp421; TAU FL – full length tau. Molecular 
mass markers in kDa are shown on the right. 
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Figure 9 - PGJ2 triggers the formation of tau aggregates 
(next page). Immunofluorescence staining of SK-N-SH cells 
treated with vehicle only (DMSO, A and D) or 20M PGJ2 (B 
and C) for 16h. Tau (green) was visualized by 
immunostaining with the pan tau antibody (Santa Cruz). 
Nuclei (red) were detected with TO-PRO-3. Merged images 
are shown for tau/To-Pro. Arrows point to large tau 
aggregates. The scale bar is = 7.3m (A), 11.9m (B), 5.5m 
(C) and 3.6 m (D). 
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Figure 10 - PGJ2 induces tau cleavage in rat (E18) primary 
cortical neuronal enriched cultures (next page). Western 
blot analyses to detect tau in total extracts of rat 
primary cortical cultures (35µg of protein/lane) treated 
with DMSO (vehicle, control, C) or with 20µM PGJ2 (T) for 
16h. The blot was probed with the TauC3 antibody (A) then 
stripped and reprobed with the pan tau clone 5 antibody 
(B). Equal protein loading (6g and 8g of protein per lane 
for cortical neurons and SK cells, respectively) was 
demonstrated by probing parallel immunoblots with the 
anti-actin antibody (C). As a positive control, TAU FL and 
TAU detected in PGJ2-treated SK-N-SH cells are shown in 
lanes 1A and 2A. TAU, tau cleaved at Asp421; TAU FL – 
full length tau.  
(D and E), TAU immunofluorescent staining (Tau C3 
antibody) of rat cortical neurons treated with 20M PGJ2 
for 16h. The arrows are pointing to dystrophic neuritis 
and the arrowheads to bulb-like accumulations of tau. The 
scale bar = 30m.  
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Figure 11 – Sedimentation velocity analysis of cell 
lysates obtained from WT5 and Muta5 stable transfectants 
incubated for 24h without and with 9M Cd2+ (next page)- 
The cleared supernatants (1mg of protein/sample) were 
fractionated by glycerol density gradient centrifugation 
(10-40% glycerol from fractions 14 to 1). Elution 
positions of the 26S and 20S proteasomes are indicated. 
(a) Aliquots (50l) of each fraction obtained from cells 
incubated without (open squares, solid lines) and with 9M 
Cd
2+
 (closed squares, broken lines) were assayed for 
proteasome peptidase activities with three different 
substrates. Values were normalized to maximal activity 
observed in WT5 and MUTA5 stable transfectants for each 
peptidase activity, respectively. The hatched area 
highlights the difference in chymotrypsin-like activity  
between untreated and Cd
2+
-treated Muta5 transfectants. 
(b) Anti-c-myc immunoblot analysis of the same fractions 
used in (a). Proteins were precipitated with acetone from 
300l of each fraction obtained from cells incubated 
without (top  panels) and with 9M Cd2+ (bottom panels). 
The arrows point to mature (#1, 24kDa) and precursor (#2, 
31kDa) forms of WT5/c-myc and mature (#3, 26kDa) and 
precursor (#4, 31kDa) forms of Muta5/c-myc. 
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Figure 12 – Ub-conjugates and synuclein co-localize in 
aggregates in Muta5 stable transfectants treated with Cd2+ 
(next page)– Double immunofluorescent staining of WT5 (a-
d) and Muta5 (a’-d’) stable transfectants incubated for 
24h with 9M Cd2+. Ub-aggregates were visualized with the 
anti-Ub conjugates (a and a’, red), synuclein with anti-
synuclein (b and b’, green) and nuclei (n) with DAPI 
(arrows in d and d’, blue). Overlapped images are shown in 
(c and c’) and in (d and d’). The scale bar = 10m.  
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Figure 13 - Proteasome activity and levels in young (Y, 1-
2 days) and old (O, 43-47 days) flies (next page) 
Cleared fly lysates and 20S proteasomes partially purified 
from rabbit reticulocyte lysates (20S, as a marker) were 
subjected to non-denaturing gel electrophoresis as 
described under “Methods”. Lysates from mixed populations 
of females and males of each age group were analyzed. The 
chymotrypsin-like activity was assessed with Suc-LLVY-AMC 
by the in-gel assay (left panel). 26S and 20S proteasomes 
were detected by immunobloting with our antibody that 
reacts with d5, a subunit of the core proteasome particle 
(middle panel). As indicated on the left, this antibody 
recognizes the symmetric [26S(2), two caps] and asymmetric 
[26S(1), one cap] 26S holoenzymes as well the 20S core 
particle. Total protein pattern was established by 
Coomassie blue staining of native gels (right panel) 
following assessment of proteasome activity with Suc-LLVY-
AMC. Similar results were obtained in at least 
quadruplicate experiments.  
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